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ABSTRACT
Optimizing a Quantitative Real-Time Polymerase Chain Reaction Protocol for the
Characterization of Gene Expression in Blood Vessel Mimics
Tristin C. McGuffick
Blood vessel mimics (BVMs) are tissue engineered blood vessels that are intended as an
intermediate testing environment for intravascular devices, such as stents. Specifically,
Cal Poly’s Tissue Engineering Lab hypothesizes that BVMs can be used to test
endothelial cell and smooth muscle cell responses to existing and new vascular stents.
Characterization techniques are required for BVMs to be accepted as a valid testing
model, prior to being employed as an in vitro model to determine the effects of medical
treatments. Quantitative real-time polymerase chain reaction (qPCR) is one available
option for evaluating gene expression of tissues. qPCR can be performed on DNA
synthesized from RNA isolated from cells, and in this application, will provide
quantitative information on what proteins where being transcribed within the cells at the
time of RNA isolation. qPCR can be used to determine the proteins expressed in BVMs
at baseline in order to then characterize changes in protein expression induced by stent
deployment within the BVM.
The aim of this thesis was to optimize existing qPCR protocols, and implement the
optimized protocols to characterize gene expression of stented and unstented blood vessel
mimics (BVMs) and cells from a donor with Diabetes grown in Cal Poly’s Tissue
Engineering Laboratory. To accomplish this goal, existing qPCR protocols were
evaluated and modified to ensure reproducible, valid results were produced. Standard
operating procedures were created for RNA isolation, cDNA synthesis, qPCR and qPCR
data analysis. Optimized qPCR methods were then applied to BVMs from umbilical and
coronary cell sources to compare the models and to study the BVM responses to stent
deployment. Additional primers were also identified for potential usage as reference
genes and as diabetic markers for diseased BVMs.
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Chapter 1. INTRODUCTION

1.1

OVERVIEW

The focus of this thesis was to characterize gene expression of stented and unstented
blood vessel mimics (BVMs) and diseased cells grown in Cal Poly’s Tissue Engineering
Laboratory. Quantitative real-time polymerase chain reaction (qPCR) had previously
been implemented within the laboratory, but prior to characterizing gene expression for
current experiments and publication-quality work, existing qPCR lab protocols required
refinement and optimization, with subsequent application to the emerging BVM models
in the laboratory.
In order to understand the significance of characterizing gene expression of BVMs it is
important to fully understand the BVM model and its intended application. The following
sections will provide relevant background on BVMs, a review of methods required to
perform qPCR and previous work performed within the lab. Each of these topics will aid
in understanding the methods and results presented in this thesis.

1

1.2

BLOOD VESSEL MIMICS

Cal Poly’s Tissue Engineering Laboratory uses tissue engineering practices to create
BVMs that resemble the anatomy of a native blood vessel. Tissue engineering is the
cultivation of cells, often times in combination with a scaffold, to create a construct that
mimics a human tissue . Most commonly, the goal of tissue engineering is to repair or
1

replace a diseased or failed tissue or organ . BVMs are a novel approach to tissue
1

engineering, as they are intended to test intravascular devices rather than replacing a
diseased or failed blood vessel.
The following sections will discuss the basis for the model, BVM design and fabrication,
and the need for a diseased model in addition to a healthy model.
1.2.1

Clinical Relevance of BVMs

BVMs are intended as an intermediate testing environment for intravascular devices, such
as stents. Stents are a common treatment option for Coronary Artery Disease (CAD), the
most common vascular disease in the United States . The following sections will briefly
2

review CAD, stents, and the BVM application to intravascular device testing. Each of
these topics aids in understanding the development and necessary characterization of the
model.

2

1.2.1.1 Coronary Artery Disease
Heart Disease is the leading cause of death in the United States, with 1 in 4 Americans
dying each year due to Heart Disease2. Furthermore, coronary artery disease (CAD) is
the most common form of heart disease that leads to morbidity2. CAD is caused by
atherosclerosis, the build up of plaque within artery walls, in the coronary artery3.
Atherosclerotic plaques have been shown to contain smooth muscle cells, macrophage
foam cells, lymphocytes, lipids, proteoglycans, collagen, elastin and calcium4. Plaque
build up narrows the lumen of the artery, impeding blood flow through the artery to
downstream tissue. The lack of nutrients and oxygen to heart tissue eventually can lead to
a myocardial infarction. A comparison of a healthy artery and an artery narrowed by
atherosclerotic plaque build up can be seen in Figure 1.

Figure 1: A healthy artery (left) compared to an artery narrowed by atherosclerotic plaque
build up (right) .
5

3

1.2.1.2 Stenting as Treatment for Atherosclerosis
Intravascular stents have emerged as the most common, effective medical treatment to
reopen a blocked or narrowed artery . Stents are most commonly deployed through a
6

balloon catheter into the lumen of the narrowed artery. Upon expansion, the stent
condenses plaque build up into the artery wall, reopening the artery and providing lasting
mechanical support. Figure 2 provides a visual representation of a stent being inflated
into a narrowed artery.

Figure 2: Pictured above is the process a balloon-expanding stent undergoes during
placement and expansion: the catheter containing the unexpanded stent is inserted into
the narrowed artery (A), the balloon is inflated forcing expansion of the stent (B), and the
balloon is deflated and the catheter is removed from the artery (C) .
5

4

A large variety of stents exist such as balloon expanding, self-expanding, biodegradable,
bare-metal, and drug eluting stents . Each of these stent types is associated with different
7

levels of endothelial adhesion at varying time points after expansion, restenosis rates and
required pre and post placement drug therapies . For all of these stent types, as well as
7

for new and emerging stent technology, it is crucial for stent developers to fully
understand how the device will interact with and impact the vascular cell lining.
1.2.1.3 BVMs as an Intermediate Testing Environment
Prior to clinical use or regulatory approval, a device, such as a stent, must typically go
through bench testing, in vitro testing, in vivo testing, and clinical trials . This process is
8

meant to ensure a device’s safety and efficacy .
8

Blood vessel mimics can potentially be used in place of, or after, bench and in vitro
testing and prior to in vivo testing, in order to determine how a stent or other intravascular
devices will interact with the vascular cell lining, as seen in Figure 3. Implementing an
intermediate testing environment can decrease cost and hopefully bring to light any
concerns prior to moving on to the more costly and time-consuming in vivo testing.

5

Figure 3: As pictured above, BVMs can potentially provide an intermediate testing
environment in between in vitro and animal testing.
Specifically, our lab hypothesizes that BVMs can be used to test endothelial cell (EC)
and smooth muscle cell (SMC) responses to new variations in stent materials, strut
thickness and design, as well as modifications in protein and drug coatings. BVMs can be
used to compare these stent variations by examining the cellular response of ECs and
SMCs in an effort to screen for the best candidate devices prior to animal testing.
1.2.2

BVM Design

BVMs are designed to mimic, in a simple way, the geometry of a native blood vessel.
The following sections will review native blood vessel anatomy and the components and
cultivation techniques of BVMs.

6

1.2.2.1 Native Blood Vessel Anatomy
Blood vessels consist of three layers surrounding a lumen containing blood, as illustrated
in Figure 4. The innermost layer, the intima, contains a lining of ECs adhered to a
basement membrane, which prevents clotting . The middle layer, the media, contains
9

SMCs and connective tissue, which aid in vasomotion . Lastly, the outermost layer, the
9

adventitia contains extracellular matrix, fibroblasts, and perivascular nerve cells,
providing support to the vessel .
9

Figure 4: Anatomy of a native blood vessel .
9

7

1.2.2.2 BVM Fabrication
As previously mentioned, BVMs are designed to mimic the geometry of a native blood
vessel, at least in a simplistic manner. BVMs are dual-sodded tissue engineered blood
vessels that contain endothelial cells and smooth muscle cells cultivated on a tubular
electrospun poly(D,L-Lactide-co-Glycolide) (PLGA) scaffold, as seen in Figure 5. Both
cell types are separately pressure sodded into the lumen of the PLGA scaffold. BVMs are
cultivated in a bioreactor system attached to an 8-roller peristaltic pump to induce
mechanical shear stress within the lumen of the vessel. The entire bioreactor system is
placed within an incubator to maintain temperature, humidity, and carbon dioxide levels.

Endothelial cell lining

Smooth muscle cell lining

Lumen

PLGA scaffold

Figure 5: BVMs contain layers of endothelial cells and smooth muscle cells sodded and
cultivated on the lumen of an electrospun PLGA scaffold.
8

1.3

TECHNIQUES FOR EVALUATING CELLS AND TISSUES

In order for BVMs to be accepted as a valid testing model it is important to characterize
the model in multiple ways. Furthermore, it is necessary to have characterization
techniques available to understand the effectiveness of medical treatments. Analyzing
BVM morphology, phenotype, and gene expression is therefore vital to validating the
model as well as characterizing the changes medical treatments induce within the model
in order to more accurately assess the medical treatment.
Methods that have been previously used to analyze human biopsies can be applied
directly to tissue engineered constructs. Basic histology, immunohistochemistry, en face
imaging, flow cytometry and polymerase chain reaction are several well-used methods
for evaluating cells and tissues .
10-13

Histology is the study of the anatomy of a tissue at the microscopic level . Histology
14

protocols require sample embedding, cryosectioning, mounting onto a slide, and
staining . Hematoxylin and eosin and Masson’s trichrome are common nonspecific
13

staining reagents that stain components within a cell such as nucleic acids, proteins,
collagen and muscle fibers . Histology stains such as these are limited to illustrating the
15, 16

structure and morphology of a tissue at a single cross section and do not distinguish
between different cell types .
15

9

Immunohistochemistry is a method that uses labeled antibodies to bind to a specific
antigen presented on a cell within a specific cross section . Immunohistochemistry is a
17, 18

highly specific evaluation technique that can distinguish between different cell types and
processes that cells within the tissue sample are undergoing, such as proliferation or
apoptosis . Immunohistochemistry requires fixation of the sample and data are limited to
17

a 2-dimensional cross section of tissue .
17, 18

En face images (which refers to images obtained from the surface of the sample) can be
obtained from tissues using a variety of instruments such as an optical microscope or a
scanning electron microscope (SEM). Fluorescent microscopes are a specific type of
optical microscope and are usually used in conjunction with a fluorescent marker; the
fluorescent marker bisbenzimide (BBI) is used within our laboratory. BBI fluorescently
stains cell nuclei blue. BBI requires fixation of the tissue, is non-specific, and shows cell
presence and spatial organization of the cells across the surface of the tissue sample .
10-13

SEM imaging of biological samples may require additional processing such as sputter
coating, depending on the instrument being used, and also provides imaging of the
surface of the tissue, although with more detailed features related to morphology .
10-13

10

In flow cytometry, cells are passed individually in a cell suspension through an
instrument that measures the returned light scatter at varying angles . Additionally,
19, 20

fluorescent markers can be employed in conjunction with flow cytometry to identify
specific internal cell components or surface antigens . Cell count, cell type and spatial
19, 20

information, among other properties, are extrapolated from measured fluorescence and
returned light scatter . While flow cytometry can generate a significant amount of
19, 20

information, because it is limited to cells in suspension it does not provide information
regarding tissue morphology or structure .
19

Qualitative real-time polymerase chain reaction (qPCR) amplifies a small target sequence
of DNA over a series of heating and cooling cycles and quantifies the amount of DNA
throughout each cycle by employing a fluorescent marker . The initial target DNA copy
21, 22

number can be extrapolated from the changes in fluorescence throughout the cycles .
21, 22

qPCR has advantages over the methods previously discussed for this application, as it
provides quantitative information on what genes are being transcribed within the cells .
23

For this application, DNA for qPCR will be synthesized from RNA isolated from BVMs,
which will provide quantitative information on gene transcription within the BVMs.
Varying degrees of the genes that are transcribed will actually be translated into proteins.
While qPCR is a relatively inexpensive and simplistic process, the analysis requires a
detailed knowledge and care as to not introduce error or misinterpret results .
24

11

qPCR provides information not obtained from current methods performed within the lab
(hematoxylin and eosin staining, SEM imaging, and BBI staining). qPCR had been
briefly introduced and used within the lab by previous students to analyze gene
expression of BVMs, however, had not been optimized or fully developed for our
application .
10, 13

1.4

QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION

In this thesis the focus was on qPCR, which has emerged as the “gold-standard” for
characterizing gene expression within a cell sample or tissue . qPCR can be used to
25

provide a baseline profile for BVMs to characterize potential alterations in gene
expression induced by stent deployment within the BVM. qPCR has been used
previously by Punchard et al to characterize changes in inflammation, apoptosis and
proliferation markers within stented and unstented tissue engineered blood vessels that
had been subjected to pulsatile flow . These same techniques can be applied to BVMs.
26

The following sections will introduce the principles and parameters of qPCR.

12

1.4.1

qPCR Principles and Parameters

qPCR provides quantitative results on gene expression by amplifying a small copy
number of a segment of DNA . In this application, the target DNA sequence that is
21, 22

amplified during qPCR is synthesized from RNA that is isolated from the sample.
Therefore, the first step of qPCR is to isolate RNA from the sample of interest . Next, a
10, 23

complimentary strand of DNA (cDNA) is synthesized from the isolated RNA .
10

Ultimately, the cDNA template, forward and reverse primers, DNA polymerase,
deoxynucleotide triphosphates (dNTPs), a fluorescent marker and water are combined in
a sample tube, and placed into a thermal cycler in order to perform qPCR . The
10

fluorescent marker fluoresces when bound to double stranded DNA, and the fluorescence
is measured throughout a series of cycles . The most significant output of a qPCR run is
27

the amplification curve, which measures the change in fluorescence throughout each
cycle . Data analysis is performed to quantify the initial copy number of the targeted
22

DNA template .
27

The following sections will describe methods employed to perform qPCR and will
introduce the parameters used to validate the described methods.

13

1.4.1.1 RNA Isolation
One way to obtain DNA for qPCR analysis, is to synthesize it from RNA. With this
specific method, the first step of qPCR is to isolate RNA from the sample of interest .
10, 13

RNA is a single stranded nucleotide chain that synthesizes proteins from DNA within a
cell . As a result, isolated RNA from a sample provides information on which proteins
28

are being transcribed within the sample at the exact time point that the sample was
harvested. It is important to note that qPCR provides information on what proteins are
being transcribed, but does not provide the quantity of the transcribed protein sequences
that are then translated into actual proteins.
During protein synthesis, a segment of messenger RNA (mRNA) is first transcribed from
DNA within the cell nucleus, resulting in an immature form of mRNA called premRNA . Pre-mRNA contains coding portions called exons and noncoding portions called
28

introns; enzymes remove introns from the pre-mRNA molecule and splice appropriate
exons together to create a functional mRNA molecule . A single pre-mRNA molecule
28

can code for multiple proteins by pairing specific exons together through alternative
splicing, as seen in Figure 6 .
28

14

Figure 6: A visual representation of alternative splicing is seen above, in which a single
pre-mRNA molecule can code for multiple proteins .
28, 29

mRNA molecules are then translated to the corresponding protein; translation most often
occurs within the cytoplasm of the cell . Not all proteins that are transcribed are then
28

translated into actual proteins. A diagram of the protein synthesis process within a cell is
provided in Figure 7.

15

Figure 7: The diagram above shows the process in which protein synthesis is executed
within a cell. First, pre-mRNA is transcribed from DNA within the cell nucleus and
processed into a functional mRNA molecule. The functional mRNA molecule is
transported to the cytoplasm of the cell, where it is translated to a protein .
28, 30

Prior to DNA synthesis from isolated RNA, it is necessary to obtain the concentration
and assess the quality of isolated RNA . Usage of low quality RNA has the potential to
31, 32

compromise qPCR results . RNA quality can be assessed using spectrophotometry
32

measurements and by performing Agarose gel electrophoresis

. RNA concentration

10, 13, 31

will be used to determine the quantity of RNA that is used for synthesizing the DNA that
is used for qPCR. RNA concentration can also be obtained from spectrophotometry
measurements

.

10, 13, 31
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1.4.1.1.1 RNA Concentration & Quality Assessments using Spectrophotometry
In spectrophotometry, three wavelengths of light (230, 260 and 280 nanometers) are
measured to assess quality and concentration . The wavelength 260 nm is specific to
32

nucleic acids (DNA and RNA), the wavelength 280 nm is specific to proteins, and the
wavelength 230 nm is specific to ethanol, salts, and other contaminants, as seen in
Table 1 .
32

Table 1: Wavelengths Measured through Spectrophotometry for RNA Quality
Assessments

32

Wavelength (nm)

Molecule(s) Targeted

280

Proteins

260

Nucleic Acids (DNA, RNA)

230

Ethanol, salts and other contaminants

17

NanoDrop is an instrument commonly used to obtain spectrophotometry measurements
and provides the user with the RNA concentration and A /A and A /A ratios . The
260

280

260

32

230

A /A ratio provides a quantitative measurement for the amount of nucleic acids in the
260

280

sample relative to proteins and the A /A ratio provides a quantitative measurement for
260

230

the amount of nucleic acids in the sample relative to ethanol, salts, and other
contaminants that may have been left over during the RNA isolation process . Ideal
32

values for the A /A and A /A ratios are 1.8 and higher and 2.0 and higher,
260

280

260

230

respectively . It is important to note that factors contributing to low A /A are not fully
33, 34

260

230

understood . Furthermore, low A /A ratios caused by guanidine thiocyanate (commonly
34

260

230

used in cell lysis buffers) contamination have not been shown to negatively affect qPCR
results .
34

Spectrophotometry measurements are not specific to RNA, and may overestimate RNA
concentration if genomic DNA contamination is present . Therefore, it is necessary to
32

employ an additional assessment technique to ensure DNA contamination is not present
when using spectrophotometry to assess RNA concentration and quality.

18

1.4.1.1.2 RNA Quality Assessments using Gel Electrophoresis
A denaturing (a process that removes the quaternary, tertiary and secondary structures in
proteins and nucleic acids) gel, such as a Tris-acetate-EDTA (TAE) Agarose gel stained
with Ethidium bromide can be used to assess RNA integrity and ensure DNA
contamination of the samples is not present . Gel electrophoresis is performed by
32, 35

passing an electrical current through an ethidium bromide stained Agarose gel that
contains the samples of interest . The samples migrate through the gel and separate based
36

on their size .
36

When high quality RNA is present, two ribosomal bands, 28S and 18S are visible, with
the 28S band approximately twice as intense as the 18S band without visible
smearing . Figure 8 illustrates two examples of high integrity RNA, two examples of
32, 35

degraded RNA and an example of an RNA sample contaminated by genomic DNA .
32, 36

Degraded RNA is evident by the smearing down the lane, as shortened fragments of
RNA will travel more quickly through the gel than intact, longer segments of RNA .
36

19

Figure 8: Pictured above are examples of high quality RNA (Lanes 1 and 2), degraded
RNA (Lanes 3 and 4), and high quality RNA contaminated with genomic DNA
(Lane 5) .
36

1.4.1.2 cDNA Synthesis
Once RNA is isolated from the sample and its quality is confirmed, complimentary DNA
(cDNA) must be reverse transcribed from the isolated RNA, as template DNA is required
for qPCR . Reverse transcriptase, primers, dNTPs, magnesium chloride (MgCl ), water,
10, 13

2

and an RNase inhibitor are added to a specified amount of RNA and heated and cooled in
a thermal cycler to create complimentary strands of DNA.

20

The reverse transcriptase synthesizes cDNA by adding the appropriate dNTPs to the
RNA sequence . Prior to reverse transcription, a primer must bind to the RNA sequence.
37

There are three different types of primers that can be used: random primers,
oligodeoxythymidylic acid (oligo-dT) primers, and gene specific primers

. A diagram

27, 37

of each of these primers can be seen in Figure 9. Random primers bind to multiple
segments along a sequence of mRNA, which results in multiple cDNA transcripts from a
single RNA sequence . Oligo-dT primers are more specific than random primers, as they
37

bind to the polyA tail of mRNA, eliminating cDNA transcription from ribosomal RNA
(rRNA) . Gene specific primers bind to a specific sequence of RNA and require separate
37

reactions for each target-specific primer selected .
37

Figure 9: Pictured above are the three different types of primers: gene specific primers,
oligo-dT primers, and random primers, which can be employed in a reverse transcription
reaction .
38

21

Upon completion of cDNA synthesis, cDNA is ready to be used in a qPCR reaction for
amplification and quantification. The following section will discuss the methods
employed in qPCR.
1.4.1.3 qPCR Methods
As previously mentioned, cDNA, forward and reverse primers, DNA polymerase,
dNTPs, a fluorescent marker and water are combined into appropriate wells within a PCR
plate and placed into a qPCR instrument . The qPCR instrument functions as both a
10, 13

thermal cycler and as an instrument to quantify fluorescence; the instrument can be
programmed to heat and cool the plate for a specified number of cycles to amplify the
target DNA sequence and to measure the fluorescence upon completion of each cycle to
quantify the amount of double stranded DNA present . A single qPCR cycle consists of
25

three actions, which occur in two stages, to facilitate DNA denaturation, primer and
probe annealing, and polymerization, as seen in Figure 10 .
25

22

Figure 10: A qPCR cycle undergoes two stages: A) denaturation of double stranded DNA
at temperatures greater than 90°C occurs in stage 1, and B) annealing of forward and
reverse primers to single stranded DNA at temperatures between 50-75°C and C)
transcription by DNA polymerase at temperatures between 72-78°C

24, 25

occur in stage 2.

First, the sample is heated to a temperature greater than 90°C to denature double stranded
DNA, resulting in two single strands of DNA, as seen in Figure 10 (A) . Next, the
25

temperature is cooled to 50-75°C for forward (backward compliment of the reverse
primer) and reverse primer annealing and DNA polymerase attachment . Forward and
25

reverse primers are designed to bind to specific portions of cDNA template in order to
amplify a specific gene of interest . Figure 11 shows a representative image of forward
27

and reverse primers for a particular gene; the DNA sequence amplified in a qPCR
reaction will begin at the forward primer and continue to the end of the reverse primer .
25

Both the forward and the reverse primer bind to the 3’ region of single stranded DNA, as
seen in Figure 10 (B) .
27

23

Figure 11: Pictured above is the mRNA sequence for IL-6 (a diabetic marker used in this
thesis). The red and green segments of nucleotides represent the selected sequences of
nucleotides for the forward and reverse primer, respectively. The DNA sequence
amplified in a qPCR reaction will begin at the forward primer and continue to the end of
the reverse primer.
Temperatures of 72-78°C provide an optimal temperature for DNA polymerase to
complete transcription . At these temperatures, DNA polymerase attaches to the forward
25

and reverse primers and transcribes towards the 5’ region, adding the appropriate dNTPs
to synthesize double stranded DNA, as seen in Figure 10 (C) .
27

The fluorescent dye binds to double stranded DNA within the sample during
polymerization and fluoresces upon binding, as illustrated in Figure 10 (C) and Figure 12.
The intensity of fluorescence is measured upon completion of each cycle in the qPCR
process and is plotted against cycle number in the resultant amplification plot . The
25, 27

relative expression of a gene to a control sample can be obtained from the amplification
plot, which is further explained in the upcoming “1.4.1.4.2 Amplification Curve”
section .
39

24

Figure 12: In Step 1 above, a fluorescent molecule binds to double stranded DNA, in Step
2 the fluorescent molecule detaches from the double stranded DNA, the DNA is
denatured, annealed and polymerized creating two identical segments of double stranded
DNA, and in Step 3 the fluorescent molecule re-binds to double stranded DNA and
fluoresces .
39

1.4.1.4 qPCR Data Analysis
As previously mentioned, the most significant output of a qPCR run is the amplification
curve, which can be used to calculate the relative expression of a specific gene of interest
to a control sample using the comparative threshold cycle method

. A reference gene

25, 27, 39

can be identified and used as an internal control to normalize the data obtained from the
amplification curve across all samples of interest . In addition to an amplification
22, 24

curve, a qPCR instrument can be programmed to generate a dissociation curve. The
dissociation curve is performed upon completion of the qPCR cycles and plots the change
in fluorescence against increasing temperatures . The dissociation curve can be used to
40

determine the specificity of the amplified DNA sequence .
40

25

The following sub-sections will briefly discuss the importance of selecting a reference
gene, how to interpret the resultant amplification and dissociation curves, and the
equations used for a comparative cycle threshold analysis.
1.4.1.4.1 Reference Gene
It is important to note that a normalization factor is required for qPCR data analysis to
account for the potential loss of sample during the reverse transcription step . Reference
37, 42

genes such as GAPDH, actins, tubulins and ribosomal RNAs are often employed as they
are required for basic cell maintenance and survival and their expression is considered to
be stable in many cell types . Despite the popularity and widespread usage of the
37

previously mentioned genes as reference genes, they have been shown to be down or up
regulated in various experiments , which can introduce error into qPCR results. As a
24

result, statistical analysis should be performed within the samples of an experimental set
up to ensure that the selected reference gene is expressed equally within all samples being
compared. Usage of a reference gene that is not equally represented within all samples of
interest will introduce error into qPCR results .
24, 37

26

1.4.1.4.2 Amplification Curve
The amplification curve plots the change in fluorescence on the y-axis (in log scale)
against cycle number on the x-axis . Theoretically, the target cDNA sequence is doubled
41

during each cycle of qPCR, resulting in an exponential plot . However, in practice three
22

phases are present in amplification plots: a stochastic, an exponential and a plateau phase,
as seen in Figure 13 . The stochastic phase is present during the first few qPCR cycles
22

(usually 10 – 15 cycles), in which the fluorescence emission upon completion of each
cycle is not higher than background fluorescence . The stochastic phase is commonly due
42

to threshold sensitivity and variability within qPCR methods and can be seen is section d
of Figure 13 . The baseline fluorescence is calculated from the stochastic phase by
37, 39

entering the cycle numbers it occurs throughout into the qPCR instrument (the baseline
cycles can be seen in portion e of Figure 13) . During the exponential phase, the qPCR
42

reaction has reached its optimal amplification period, with the template DNA sequence
doubling during each of the cycles . In theory, this only occurs for a few cycles during a
42

qPCR run . The last phase of an amplification plot is the plateau phase (sections a and b
22

in Figure 13), in which fluorescence measurements are no longer useful for data
analysis . This is most commonly due to limited reagents within the reaction .
42

22, 42

27

Figure 13: Pictured above is a typical amplification curve exhibiting the plateau phase (a
and b), exponential phase (c), stochastic phase (d) and baseline cycles (e) . The threshold
39

cycle is set in the middle of the exponential phase (c) .
39

The middle of the portion in which fluorescence significantly increases over the
background fluorescence is the cycle threshold, as demonstrated in Figure 13 . The cycle
42

threshold is most commonly set in the middle of the exponential phase and is the value
used to calculate relative expression of a particular marker to a control sample

28

.

10, 13, 39

1.4.1.4.3 Comparative Cycle Threshold
Data analysis can be performed using the comparative threshold cycle method, which
measures the relative expression of a target gene to a reference gene . Upon completion
10, 37

of a qPCR cycle, samples are normalized by subtracting the average reference gene
threshold cycle value from the average threshold cycle value for each experimental
sample, as seen in Equation 1. Fold change data is then obtained by subtracting the
average change in threshold cycle of the control samples from the average change in
threshold cycle of the experimental samples, as seen in Equation 2, and using this value
in Equation 3. A thorough protocol for qPCR data analysis is provided in “Appendix G:
qPCR DATA ANALYSIS PROTOCOL (SOP7106).”
Equation 1: Cycle Threshold (Ct) Normalization of Sample to Reference Gene
∆Ct= Ctmean sample - Ctmean reference gene

Equation 2: Calculation of ΔΔCt Values
∆∆Ct=∆Ctexperimental samples -∆Ctcontrol samples

Equation 3: Calculation of Fold Change
Fold Change=2-(∆∆Ct)

29

1.4.1.4.4 Dissociation Curve
The dissociation curve measures change in fluorescence as temperature increases and can
be used to confirm the presence of single, specific DNA segments in a PCR reaction .
40

Dissociation curves are commonly implemented in qPCR reactions using non specific
fluorescent dyes, as these molecules will bind to any double stranded DNA sequence and
can therefore emit fluorescence when not bound to the targeted DNA sequence . As
41

temperature increases, double stranded DNA denatures, causing the fluorescent molecule
to unbind, resulting in a decrease in fluorescence. Molecules of shorter length have lower
melting temperatures than molecules of longer lengths . Theoretically, all DNA segments
41

in the reaction of the same length will melt at the same temperature. Figure 14 displays
an ideal dissociation curve with a single peak in which all amplified DNA segments melt
at the same temperature.

Figure 14: Pictured above is an ideal dissociation curve for a specific gene; all amplified
DNA segments visibly melt at the same temperature.
30

Primer-dimer is the action of forward and reverse primers interacting with themselves or
each other and may result in the following structures: a hair pin (intermolecular
interactions within a single primer), a self-dimer (intermolecular interactions between
two identical primers), and a cross dimer (intermolecular interactions between two
different primers) . Primer-dimer formation results in much short segments of double
43

stranded DNA that melt at lower temperatures than the longer, targeted DNA sequence .
41

When primer-dimer formation occurs, it is evident through multiple peaks on the
dissociation curve, as seen in Figure 15.

Figure 15: Pictured above is dissociation curve that may show primer-dimer formation,
evident by multiple peaks.

31

1.4.2

Utility of qPCR for BVMs

In summary, qPCR can be utilized to characterize alterations in gene expression within
cells and tissues at a specific time point. These changes are indicative of what proteins
are being transcribed for within the cell . Proteins provide valuable information regarding
28

cell function and cell and tissue response to external and environmental stimuli, such as,
but not limited to, stenting .
26, 28

Prior to performing qPCR, it is important to understand the principles employed in order
to accurately assess the validity of the results obtained . When performed accurately,
45

qPCR has the potential to provide information on what changes stenting induces on gene
expression within our models . Furthermore, it provides the ability to compare BVMs
26, 45

from different cell sources to quantify the differences in gene expression and/or
similarities between the different sources.
1.5

EMERGING TYPES OF BVMs WITHIN THE TISSUE ENGINEERING
LAB

Previously, BVMs have been limited to ECs and SMCs from healthy umbilical veins and
arteries . The lab has recently begun cultivation of BVMs from an alternate source, the
10

coronary artery . ECs and SMCs from the coronary artery are potentially more
13

physiologically accurate for a preclinical model, as they are from the location that
intravascular devices, such as stents, are placed. Furthermore, coronary artery cells from
diabetic patients have been utilized as the cells grown in BVMs in an attempt to create a
model to represent an artery of a patient with diabetes.
32

ECs and SMCs from the umbilical vein and artery are easier to work with and are less
expensive than healthy and diabetic ECs and SMCs from the coronary artery. Current
techniques employed within the lab (SEM and BBI imaging and hematoxylin and eosin
stains) provide information regarding the morphology of the cells and the intravascular
cell lining but do not characterize changes in gene expression within the models . This
10,13

further supports the need for more elaborate and specific characterization techniques,
such as qPCR. Understanding the emergence and advantages of different types of BVMs
will lay the foundation for the samples that qPCR was applied to in this thesis.
1.6

BENEFITS OF DISEASED MODELS

Medical treatments for CV disease, such as stents, are placed in diseased individuals.
Many of these patients experience restenosis, or re-narrowing, of the stented artery . The
47

causes of restenosis are not fully understood . As a result, preclinical animal models of
47

disease are commonly implemented to further understand the pathology within a diseased
individual and to more accurately assess and characterize medical treatments in a setting
that more closely mimics that patient popoulation .
48, 49

1.6.1

Animal Models of Disease

Researchers currently employ a large variety of small and large diseased animal models
for cardiovascular (CV) disease including primates, swine, rabbits and rats . One
48, 49

limitation to all animal models is that they can be very expensive and require additional
personnel training. It is important to note that the larger the animal model and the longer
the life span of the animal, the more expensive the model becomes .
49

33

Primates, such as chimpanzees and rhesus monkeys, have been identified as some of the
most physiologically accurate animal models for CV disease as they eat diets similar to
humans and naturally develop CV disease . Unfortunately, primates require experiments
49

with extended time points for analysis as they have long life spans and do not respond
quickly to treatments and diet changes, can carry diseases that are dangerous to humans,
and their usage is ethically questionable . Therefore, they are rarely used as preclinical
49

models for testing vascular devices.
Swine, like primates, have similar diet preferences to humans and, with appropriate diet
modifications, naturally exhibit atherosclerosis . Pigs also have a similar cardiovascular
49

system to humans, which is beneficial for medical device testing . Pigs are, unfortunately,
49

expensive and require unique facilities due to their large size .
49

Rabbits are smaller and less expensive than primates and pigs . Although rabbits do not
49

naturally develop atherosclerosis, vascular lesions can be induced with a high-cholesterol
diet . The iliac artery is commonly studied within rabbit models, as the size is optimal for
49

many vascular therapies . Lesions formed within rabbits are different than those formed
48, 49

in humans, however have still been useful in studying new therapies and response
mechanisms to injury .
48
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Rat and mouse models are common as they are less expensive than larger animal models
and many genetic modifications exist . Genetic modifications are required within both
48, 49

rat and mouse models because these animals do not develop atherosclerosis . Corpulent
49

rats and knockout mice are both genetically modified strains that are used to study CV
disease. Corpulent rats are obese, hypertensive, exhibit hyperlipidemia, and develop
lesions . Knockout mice, particularly ApoE mice, exhibit high cholesterol and lesions,
49

-/-

which increase when fed a high cholesterol diet .
49

Many animal models currently exist to study CV disease and to assess new therapies;
each model has their respective benefits and limitations. However, an ideal animal model
doesn’t currently exist for CV disease .
48

1.6.2

Diabetes as a Disease of Interest

One particular disease of interest, for this thesis and for the field of intravascular devices
in general, is diabetes. Diabetic patients experience an increased prevalence of CAD
when compared with non-diabetics . Furthermore, diabetics have been shown to respond
50

to vascular treatments differently than non-diabetic patients and have a higher rate of
restenosis following vascular stenting than non-diabetics .
46, 47

Therefore, there is a need to better understand the mechanisms of CAD in a diabetic
patient and to assess their response to vascular therapies. The following section will
introduce the potential for BVMs to serve as a diabetic diseased model. A more thorough
discussion of the genetic markers employed in this thesis for characterization of diabetic
BVMs will be provided in Chapter 3.
35

1.6.3

Potential for BVMs to Serve as Diabetic Disease Models

In addition to serving as simple mimics of “healthy” blood vessels for intravascular
device testing, it is also possible that BVMs could be designed to serve as disease
models. Theoretically, a diseased BVM can be created by using ECs and SMCs from a
diseased individual or by mimicking the environment of a diseased individual. Usage of a
BVM to study disease pathology or cell response to a medical treatment could potentially
be more cost efficient than the alternative animal models, while providing more
physiologicially relevant preliminary results in the testing and evaluation process. The
more complex the cell sources or overall BVMs become, the more important it will be to
have specific and well-developed characterization techniques.
1.7

PREVIOUS WORK APPLYING qPCR TO HEALTHY AND DISEASED
BVMs

1.7.1

Work by Michael Gibbons and Sarah Ur

The Cal Poly Tissue Engineering lab has previously explored the implementation of
qPCR for analyzing BVMs . Michael Gibbons and Sarah Ur’s senior project had three
10

components. First, they created and validated a BVM cultivation protocol for a PLGA
scaffold. Second, they applied and modified, as needed, the previously created BVM
protocol to an ePTFE scaffold. Lastly, they implemented a qPCR protocol to study gene
expression within the BVMs .
10
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Michael and Sarah found that sodding two cell types, human umbilical vein endothelial
cells (HUVECs) and human umbilical artery smooth muscle cells (HUASMCs) was
necessary to obtain the cell adhesion confluency desired within both scaffold materials.
Furthermore, they created a preliminary protocol for qPCR. They selected and designed
the following genes for qPCR analysis: an endothelial cell marker (PECAM), an
inflammation marker (ICAM), a proliferation marker (Ki-67), an apoptosis marker
(BAX), and a reference gene (GAPDH).
Sarah Ur performed an additional project, in which she implemented a new cell source,
the coronary artery . ECs and SMCs from the coronary artery were used with the
13

intention of being more biologically relevant; as they come from the location that
vascular coronary artery stent will be deployed. These experiments were also included for
the new qPCR approaches.
Sarah performed qPCR on the following cell types throughout varying passage numbers
during cell expansion: human umbilical vein endothelial cells (HUVECs), human
umbilical artery smooth muscle cells (HUASMCs), human coronary artery endothelial
cells (HCAECs), human coronary artery smooth muscle cells (HCASMCs), and diabetic
human coronary artery endothelial cells (DHCAECs). Additionally, Sarah performed
qPCR, scanning electron microscopy (SEM) and hematoxylin and eosin stains on
coronary and umbilical BVMs to characterize gene expression, cell morphology and
distribution throughout each model.
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No concrete, significant trends were seen for any of the genes studied in HUVECs,
DHCAECs, HCASMC, and HUASMCs. HCAECs underwent a change in gene
expression after passage 7 in a cell culture flask, as an up regulation in ICAM and down
regulation in PECAM was seen. SEM imaging and hematoxylin and eosin stains
demonstrated nearly confluent cell linings in both coronary and umbilical BVMs. qPCR
results showed trends in down regulation in the endothelial cell marker, inflammation
marker and apoptosis marker and up regulation in the proliferation marker in coronary
BVMs when compared to umbilical BVMs, although the sample number was not large
enough to make definitive conclusions. However, this preliminary work laid the
foundation for the lab’s more recent experiments and for the protocol development and
implementation described in this thesis.
1.8

SUMMARY AND AIMS OF THE THESIS

BVMs can provide an intermediate testing environment for intravascular devices, such as
stents. Stents, a common treatment for atherosclerotic plaque formation that is impeding
blood flow within an artery, are deployed to reopen the vessel wall and provide
mechanical support in a narrowed artery. BVMs can be used to test and compare EC and
SMC responses to novel stent designs such as new protein coatings, strut designs and
stent materials.
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While many techniques exist for evaluating BVMs and other engineered tissues,
including flow cytometry, histology, immunohistochemistry, and en face imaging, there
is a need to obtain more detailed results. qPCR provides a quantitative method to study
the differences in gene expression between BVMs from varying cell sources as well as
the alterations in gene expression each BVM undergoes after stent deployment. Although
a previous student project looked at implementing qPCR for characterization of BVMs,
the findings were inconclusive and the protocol was in need of refinement and
optimization.
Therefore the overall goal of this thesis was to optimize and implement qPCR for
evaluating healthy and diseased BVMs. To accomplish this goal, the first aim was to
optimize the qPCR protocol used in Cal Poly’s Tissue Engineering Laboratory on both
flasks of cells and BVMs to ensure reproducible, valid results were produced. The second
aim was to apply the optimized protocols to umbilical and coronary blood vessel mimics
to compare the models and to study the BVM responses to stent deployment. The third
aim was to research and implement additional primers to be used as reference genes and
as diabetic markers for the diseased BVMs. Standard operating procedures established
through this work can serve as a standard for future lab members performing qPCR,
primers can be used for healthy and diabetic BVMs, and the data generated can serve as a
baseline for future studies and comparisons.
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Chapter 2. ESTABLISHMENT AND OPTIMIZATION OF TECHNIQUES AND
PROTOCOLS FOR QUANTITATIVE REAL-TIME POLYMERASE CHAIN
REACTION OF BLOOD VESSEL MIMICS

2.1

INTRODUCTION

qPCR is a very simplistic process that requires immense knowledge of data output and
processing to ensure valid results are produced . Furthermore, the BVM is a unique
24, 31

sample (cells cultured on PLGA), which required minor modification of protocols
provided by manufacturers. As described in Chapter 1, qPCR consists of isolating mRNA
from the sample, making complimentary DNA from the isolated RNA, preparing and
running qPCR with the complimentary DNA, and, lastly, performing data analysis of
results obtained from the qPCR run . A full schematic of the various protocols
10, 13

employed for a successful qPCR protocol can be seen in Figure 16.
Michael Gibbons and Sarah Ur previously implemented a qPCR protocol within the
lab . However, their protocols required refinement and optimization. The following
10, 13

sections will discuss the kits and technologies used within the lab and discuss
modifications made to existing protocols.
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Figure 16: A schematic of the various protocols employed for a successful qPCR
experiment .
42
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2.2

COMMERICAL KITS AND TECHNOLOGIES EMPLOYED

A variety of reliable commercial kits exist that provide consistency and a form of quality
control for each portion of the qPCR protocol . Furthermore, commercial kits are fairly
37

simple and convenient to implement for a particular application, and, once implemented
and optimized within a lab, have the potential to provide consistent, uniform results .
37

RNeasy Mini Kit (QIAGEN), iScript cDNA synthesis kit (Bio-Rad Laboratories), and
Fast SYBR Green Master Mix (Life Technologies) were continued to be utilized for
RNA isolation, reverse transcription and qPCR, respectively, within the lab. Each of
these kits had been previously selected and implemented for analysis of BVMs grown in
Cal Poly’s Tissue Engineering Lab by Michael and Sarah . The following sections will
10,13

briefly introduce the principles, components, and advantages to each of the kits
employed.
2.2.1

RNeasy Mini Kit (QIAGEN) for RNA Isolation

The RNeasy Mini Kit utilizes silica spin column technology and centrifuging to isolate
up to 100 μg of RNA (200 base pairs and longer) from a variety of cell types . The usage
51

of a spin column containing a silica-based membrane in combination with high-salt
buffer solutions facilitates RNA binding to the silica-based spin column . Bound RNA
51

can then be purified by washing the spin column with buffers. Centrifugation of a spin
column containing RNA and buffer solution washes the RNA with buffer solution,
resulting with purified RNA bound to the spin column and a flow through solution below
the spin column that is discarded .
51

42

Figure 17 diagrams the procedure used to isolate RNA using the RNeasy Mini Kit. First
cells are lysed and homogenized with a QIAshredder spin column . The cell lysate
51

solution employed by QIAGEN contains a high concentration of guanidine-thiocyanate to
inactivate potentially harmful RNases that may degrade intact RNA . Ethanol is added to
51

the homogenized cell lysate to promote ideal binding conditions . The ethanol cell lysate
51

solution is centrifuged through an RNeasy Mini spin column, resulting in binding of total
RNA to the silica-based spin column membrane . The RNeasy spin column (containing
51

bound total RNA) is then washed with a series of buffers by adding the buffers to the top
portion of the spin column and centrifuging . Upon completion of the washing portion,
51

RNase free water is added to the RNeasy spin column, causing total RNA to be released
and eluted into the RNase free water .
51
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Figure 17: The following methods, as diagrammed above, are performed to isolate RNA
using the RNeasy Mini Kit: cells are lysed, homogenized with a QIAshredder spin
column, ethanol is added to homogenized cell lysate, centrifuged through a RNeasy Mini
spin column to facilitate binding of RNA, washed with a series of buffers, and eluted .
51
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Qiagen’s RNeasy Mini kit is commonly employed for RNA isolation by other research
groups . Furthermore, Punchard et al used the RNeasy Mini Kit to isolate RNA from a
26, 52

tissue engineered blood vessel that contained HUVECs seeded onto a fibronectin coated
silicone scaffold, which is a very similar sample to the BVM . Qiagen’s RNeasy Mini Kit
26

is also convenient, as it contains all components required for the protocol (with the
exception of the QIAshredder columns, which must be purchased separately, and ethanol,
which most labs contain). As a result, the RNeasy Mini Kit was continued to be utilized
for RNA isolation within the lab.
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2.2.2

iScript cDNA Synthesis Kit (Bio-Rad) for Reverse Transcription

Bio-Rad’s iScript cDNA Synthesis Kit can be used for reverse transcription of cDNA.
The kit is extremely simple to use, as it only contains three components (iScript reaction
mix, iScript reverse transcriptase and nuclease-free water) . iScript reaction mix contains
53

both oligo-dT primers and random hexamer primers (random oligonucleotide sequences
containing 6 base pairs) . Random primers are non-specific and therefore bind to multiple
53

segments along a sequence of mRNA, while oligo-dT primers are more specific and bind
only to the polyA tail of mRNA . The combination of both of these types of primers
37

increases the compatibility of the kit with many targets sequences . iScript reverse
53

transcriptase is RNase H+ and contains an RNase inhibitor to prevent degradation of the
sample . A specified volume of RNA template, nuclease-free water, iScript reaction mix
53

and iScript reverse transcriptase are combined within a nuclease-free tube and place
within a thermal cycler . The thermal cycler is programmed to incubate the samples for a
53

specific amount of time at varying temperatures, as recommended by

Bio-Rad . Upon
53

completion of the thermal cycles, resultant cDNA is diluted and ready for qPCR .
53

Like the RNeasy Mini Kit, iScript cDNA Synthesis kit is commonly used by researchers
for reverse transcription of cDNA prior to qPCR . Furthermore, its efficiency, simplicity
54, 55

and convenience makes it an optimal reverse transcription kit.
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2.2.3

Fast SYBR Green Master Mix (Life Technologies) for qPCR

Fast SYBR Green Master Mix is an extremely convenient kit to implement for qPCR
protocols, as it contains all components required for DNA amplification in a single
solution, with the exception of experiment-specific primers, cDNA template, and water .
39

Fast SYBR Green Master Mix contains SYBR Green I dye, AmpliTaq fast DNA
polymerase, uracil-DNA glycosylase (UDG), ROX passive reference dye, dNTPs and
buffer . Prior to a qPCR reaction, appropriate volumes of Fast SYBR Green Master Mix,
39

primers, and water are combined into a qPCR master mix. First, cDNA template is input
into appropriate wells on a 96-well plate, followed by the appropriate primer’s qPCR
master mix.
AmpliTaq fast DNA polymerase synthesizes double stranded DNA by adding the
appropriate dNTPs . SYBR Green I dye is a non-specific intercalating dye (binds to
39

double stranded DNA) and fluoresces when bound . ROX passive reference dye is
39

included as an internal control to normalize SYBR Green signal during data analysis .
39

SYBR Green kits exist from a variety of vendors and are commonly used for qPCR .
54, 55

Fast SYBR Green Master Mix continued to be utilized through the qPCR protocol, as it
was simple and convenient, and no apparent problems existed.
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2.3

MODIFICATIONS TO EXISTING METHODS

The following sections will discuss difficulties encountered and subsequent modifications
made to existing protocols for RNA isolation and quality assessments, cDNA synthesis,
qPCR and data analysis. Please note a large amount of unforeseen complications were
encountered in addition to those discussed in the following section. A comprehensive list
of complications encountered, but not listed here, can be seen in “Appendix A: LIST OF
EQUIPMENT MALFUNCTIONS & UNFORESEEN DIFFICULTIES.”
2.3.1

RNA Concentration

Initially, the RNA concentrations obtained from BVMs were inconsistent and inadequate.
They were often far too low to move forward in the protocol. As a result, the method for
RNA isolation from a BVM needed to be modified.

48

2.3.1.1 Minimum RNA Concentrations Required
Michael and Sarah had previously determined that a minimum of 1000 ng of RNA was
required for the reverse transcription portion of the protocol . Furthermore, the protocols
10

provided by Bio-Rad for the iScript cDNA synthesis limit the volume of RNA that can be
used for a single reverse transcription reaction to 15 μL . The minimum RNA
53

concentration required for qPCR can be calculated by inputting these constraints into
Equation 4, seen below, and solving for the “Minimum Concentration of RNA Sample.”
Manipulation of Equation 4 and input of the following values provides the minimum
RNA concentration required for cDNA synthesis: 15 μL for “Volume of RNA” and 1000
ng for “Mass of RNA Template” . The minimum RNA concentration required is 66
53

ng/μL.
Equation 4: Equation for Volume of RNA Required for Reverse Transcription

Volume of RNA=

Mass RNA Template
Concentration of RNA Sample

Minimum Concentration of RNA Sample=

Mass RNA Template
Volume of RNA

Minimum Concentration of RNA Sample=

49

1000 ng
ng
=66.7
15 uL
uL
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2.3.1.2 Previous Methods Employed for Dilution of RNA and Necessary Modification
Previously, upon completion of RNA isolation, the spin column was diluted with a
specific volume (generally 30 μL) of RNase free water . The flow through was then re10

applied to the spin column in order to re-concentrate the sample . The resultant volume of
10

RNA was equal to the volume of RNase free water initially used to dilute the spin
column.
Upon further investigation, applying an equal volume (generally 30 μL) of fresh RNase
free water to the RNeasy spin column increased RNA yield. While the resultant
concentrations were generally lower than those seen with the previous method, they were
still sufficient for cDNA synthesis (66 ng/μL or higher, as explained in the above section
“2.3.1.1 Minimum RNA Concentrations Required.” Furthermore, a higher mass of RNA
was present, providing more RNA to be used in downstream applications such as qPCR.
2.3.2

RNA Quality

Previously, A /A ratios were inconsistent and, often times, lower than the ideal value of
260

280

2.0 . Furthermore, RNA quality was previously assessed using only spectrophotometry
33, 34

measurements. As a result, modification to the RNA isolation methods in order to
increase the A /A ratios and implementation of an additional RNA quality assessment
260

280

method, such as gel electrophoresis, was necessary.
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2.3.2.1 Inadequate A /A Ratio
260

280

Values obtained from the spectrophotometry measurements for the A /A ratio were
260

280

inconsistent, and often times, far below the ideal value of 2.0 . The following three wash
33, 34

cycles are employed during RNA isolation using the RNeasy Mini Kit: once with RW1
Washing Buffer and twice with Buffer RPE, as seen in “Appendix B: RNA ISOLATION
PROTOCOL (SOP7100)”. Both RW1 Washing Buffer and Buffer RPE are wash buffers
provided in the RNeasy Mini Kit.
A modification was made to the last wash with Buffer RPE. After applying the
appropriate volume of Buffer RPE and prior to centrifuging, the spin column was allowed
to sit for 5 minutes. Allowing Buffer RPE to incubate on the spin column for 5 minutes
prior to centrifugation increased the 260/280 values to 2.0 consistently.
2.3.2.2 Gel Electrophoresis for RNA Quality
As previously explained in “RNA Concentration & Quality Assessments using
Spectrophotometry”, spectrophotometry measurements are not specific to RNA .
32

Therefore RNA concentrations may be overestimated if DNA contamination is present.
As result, an additional method was required to provide a more thorough RNA quality
assessment.
Gel electrophoresis was implemented within the lab in order to ensure that all samples
contained high quality, intact RNA that was free of DNA contamination. Gel
electrophoresis protocols are described in “Appendix C: RNA QUALITY
ASSESSMENTS PROTOCOL (SOP 7102)."
51

2.3.3

Implementing Melting Temperature Analysis for Primer Validation

Previously, dissociation curves had not been implemented within the lab. Dissociation
curves are performed upon compeltion of a qPCR cycle and measure the change in
fluorescence as temperature increases. The resultant dissociation curve provides
information about the specificity of amplicons within a qPCR reaction and can be used to
confirm the presence of single, specific DNA segments . A thorough discussion of
40

dissociation curves has been previously provided in “1.4.1.4.4 Dissociation Curve.”
Dissociation curves were added to existing qPCR protocols, as seen in “Appendix F:
qPCR PROTOCOL (SOP7105)”, to ensure that they are included in all qPCR runs
performed in the lab. Furthermore, dissociation curves were performed for all qPCR runs
performed in this thesis.
2.3.4

Optimization of Primer Design Protocols

Existing protocols for primer design utilized GenBank (National Center for
Biotechnology Information) to identify the genetic sequence for the gene of interest,
Primer3 software (University of Massachusetts Medical School) to identify possible
forward and reverse primers for the gene of interest, and Primer-BLAST software
(National Center for Biotechnology Information) to select optimal forward and reverse
primers based on their homology with non-target genes. Selected primers were ordered
from Integrated DNA Technologies (IDT) . Forward and reverse primers were designed
10

to be approximately 18 – 22 base pairs, with a targeted amplicons length ranging
from180 – 220 base pairs, and a melting temperature between 59 – 60°C10.
52

An additional primer design program, Net Primer (PREMIER Biosoft), was employed for
further analysis of selected forward and reverse primers. Net Primer prompts the user to
input selected forward and reverse primer sequences, analyzes the sequences, and
provides a quantitative rating on the efficiency of the primer in the form of a percentage.
A rating of 95% or higher is desired, although this is not always possible (verbal
communication with Dr. Peterson). Net Primer analyzes a variety of components of the
input primers such as, but not limited to, the molecular weight, guanine-cytosine content,
melting temperature, and the affinity of the selected sequences to form hairpins, selfdimers and cross-dimers.
Additionally, IDT’s website contains a primer design software, PrimerQuest, that
identifies possible forward and reverse primers for a specific gene of interest. This
software was used in place of the previously used software, Primer3 (University of
Massachusetts Medical School). Both software programs performed the same function,
however, IDT allows the user to directly order the selected primer sequences.
Protocols for primer design were modified to include Net Primer (PREMIER Biosoft),
and PrimerQuest (IDT). Primer3 (University of Massachusetts Medical School) was
removed from the protocol. Updated primer design protocols can be seen in “Appendix
E: PRIMER DESIGN PROTOCOL (SOP7104).”
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2.3.5

Reference Gene Selection and Optimization

GAPDH had previously been employed as a reference gene for all experiments within the
lab, however equal expression of GAPDH in all samples of interest had not been
confirmed . Prior to normalizing a set of samples with a reference gene it is vital to
10,13

confirm that the reference gene is indeed expressed equally within all samples. Usage of
a reference gene that is not expressed equally within all samples of interest introduces
error into qPCR results .
24

A one-way ANOVA statistical test should be employed on cycle threshold values
obtained for all sample groups for each gene of interest. If a significant difference is not
present within the samples of interest, the selected gene can be used as a reference gene.
Reference gene analysis must be performed for every experiment, as variation may occur
between different experimental set ups. A portion was added to the qPCR data analysis
protocol to ensure that all reference genes are assessed appropriately, which can be seen
in “Appendix G: qPCR DATA ANALYSIS PROTOCOL (SOP7106).”
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2.3.6

Data Analysis Modifications

Data analysis was previously performed using the comparative threshold cycle method .
10

Utilization of these methods were continued in this thesis, however, were slightly
modified to include a section that prompts the user to inspect all data for each sample
group prior to analysis in order to identify and remove any outliers. Outliers may exist for
a variety of reasons such as user error (pipetting errors or misplacement of appropriate
samples into incorrect wells) and experimental errors (contamination, bubbles in well,
etc). Any wells from a single sample group for a particular gene of interest should be
considered an outlier and therefore excluded from data analysis if either of the following
is true: the slope on the amplification plot of the sample is different than the other
replicates for that particular sample and gene of interest, which can be seen in Figure 18,
or the sample displays a melting temperature different than other samples for the same
gene of interest on the dissociation curve, which can be seen in Figure 19. Analysis and
removal of existing outliers will increase the accuracy and reproducibility of qPCR
results .
31
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Figure 18: Pictured above is an example of an outlier, the sample on the far left in green
does not have the same slope as the other samples in the sequence and was therefore
excluded from analysis.

Figure 19: Pictured above is an example of a dissociation curve that contains an outlier.
The sample corresponding to the smaller melt curve in red was not included in data
analysis.
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2.4

RESULTS

After going through each of the steps required for qPCR, and modifying or optimizing as
described in Section 2.3, the result from this aim was a final protocol that could be used
on cells or BVMs for gene expression analysis. These protocols are documented in detail
in Appendix B: RNA ISOLATION PROTOCOL (SOP7100) Appendix G: qPCR DATA
ANALYSIS PROTOCOL (SOP7106)
The following is a summary of the final protocols employed in this thesis. BVM
segments were transferred from an -80º C freezer to the bench top and segments
containing residual media were rinsed with DCF-PBS. RNA was immediately isolated
using the RNeasy Mini Kit (QIAGEN). Buffer RLT (cell lysate) was applied directly to
the BVM segment and vortexed for 5 minutes to remove RNA from BVMs. A
spectrophotometer (Nanodrop 2000, Thermo Scientific) was used to quantify the
concentration and to assess RNA quality. Gel electrophoresis was also performed on
RNA samples to confirm purity and integrity.
cDNA was transcribed using the iScript cDNA Synthesis Kit (Bio-Rad) according to
manufacturer’s instructions. A total reaction volume of 20 uL was used containing 1000
ng of RNA. cDNA was stored in a -20º C freezer.
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Quantitative PCR was performed using 96-well plates, Fast SYBR Green Master Mix
(Life Technologies), and Applied Biosystems 7500 Fast Real-Time PCR System
(Applied Biosystems). Each reaction consisted of 5 uL Fast SYBR Green, 3.2 uL cDNA
template, 0.6 uL of the appropriate 10uM primer and 11.2 uL water. 3 technical replicates
of each sample and 1 non-template control were performed for each gene of interest. Raw
data was obtained from the SDS software of the Applied Biosystems 7500 Fast RealTime PCR System.
Threshold cycle values were obtained, outliers were identified and removed, and
averages were obtained for all sample groups (including all replicates performed) for
each gene of interest. The expression of reference genes in all samples groups was
assessed by performing a one-way ANOVA on the average cycle threshold values.
Samples were then normalized to the selected reference gene and fold change values
were obtained.
2.5

DISCUSSION AND CONCLUSION

Through the work documented in this chapter, existing protocols were optimized,
resulting in establishment of a set of Standard Operating Procedures that will be used for
the remainder of this thesis. Furthermore, these protocols will be a set of Standard
Operating Procedures that can be used by future students to assess gene expression within
BVMs. However, limitations exist within the final protocols that should be addressed in
future work.
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First, a ladder should be implemented for all gel electrophoresis experiments performed.
A ladder contains samples of varying, known lengths and functions as a control in gel
electrophoresis. A ladder will provide the user with a control to evaluate the samples
included in any gel electrophoresis experiments. Furthermore, Agarose gel
electrophoresis should be performed on new primers implemented within the lab, in
conjunction with a ladder, to ensure qPCR amplicons are indeed of the length they were
designed to be. The usage of a ladder will allow the user to confirm the amount of base
pairs contained in qPCR amplicons (resultant segments of DNA amplified during a qPCR
reaction).
Selecting forward and reverse primers that span an intron sequence can further optimize
primer design. This is a precautionary measure that prevents amplification of DNA
contamination in qPCR. The cycles of denaturing, annealing and polymerizing are set to
specific time points and therefore only permit polymerization of DNA of a specific
amount of base pairs. Because introns are spliced from RNA, reverse transcribed cDNA
would be much shorter than contaminated DNA (as the contaminated DNA would
contain both introns and exons) and would not have enough time to complete
polymerization during a qPCR cycle. Primers employed in this thesis do not span intron
regions, as they were difficult to find for the selected genes.
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Overall, the kits (RNeasy Mini Kit, iScript cDNA Synthesis Kit and Fast SYBR Green
Master Mix) previously implemented within the lab were convenient and only required
minor modifications to increase efficiency. Each of these kits are commonly used by
researchers to perform qPCR due to their consistency, reliability and ease of use
a result, they were continued to be utilized within this thesis.
The next aim of the thesis was to use the modified techniques to perform qPCR on
umbilical and coronary BVMs and diabetic endothelial and smooth muscle cells.
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Chapter 3. GENE EXPRESSION IN UMBILICAL AND CORONARY BLOOD
VESSEL MIMICS AND DIABETIC CORONARY ARTERY ENDOTHELIAL
AND SMOOTH MUSCLE CELLS

3.1

INTRODUCTION

Standard Operating Procedures were created for RNA isolation, RNA quality
assessments, cDNA synthesis, qPCR methods and data analysis, as described in Chapter
2 and documented in detailed protocols in Appendix B: RNA ISOLATION PROTOCOL
(SOP7100) through Appendix G: qPCR DATA ANALYSIS PROTOCOL (SOP7106).
These Standard Operating Procedures were utilized to isolate RNA, synthesize cDNA,
and perform qPCR for the following samples: unstented coronary and umbilical BVMs
that had been cultivated for either 1 day or 3 days, stented umbilical and coronary BVMs
that had been cultivated for 3 days, and diabetic human coronary artery endothelial cells
(DHCAECs) and diabetic human coronary artery smooth muscle cells (DHCASMCs) of
varying passage number. See “Table 2: List of Sample Groups” for a visual breakdown of
all sample groups analyzed in this portion of the thesis.
These samples were selected in order to identify similarities and/or differences in gene
expression between umbilical and coronary BVMs, to characterize changes in gene
expression induced by stent deployment within coronary and umbilical BVMs, and to
characterize changes in gene expression occurring as DHCAECs and DHCASMCs age.
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This chapter will discuss the additional selection of primers for a diabetic BVM,
comparison of gene expression of potential reference genes for application in BVMs, and
the qPCR results obtained for umbilical and coronary BVMs and diabetic cells cultured
in flasks.
Table 2: List of Sample Groups

Healthy Cells

Healthy BVMs

Diseased Cells

HUVECs

1 Day Unstented
Umbilical

DHCAECs

HUASMCs
HCAECs
HCASMCs

Diseased BVMs*

DHUASMCs
3 Day Unstented
Umbilical
3 Day Stented
Umbilical
1 Day Unstented
Coronary
3 Day Unstented
Coronary
3 Day Stented
Coronary

* Please note, diseased BVMs were not included in this thesis as the -80°C freezer in
which they were stored malfunctioned, rendering the samples unusable.

62

3.2

DIABETIC MARKERS

As previously mentioned, BVMs can potentially serve as a diseased model. In order for
BVMs to serve as a diseased model it is important to characterize the model and confirm
that our model does indeed mimic (at least in some way) the behavior or dysfunction seen
in a diabetic individual. In order to characterize the gene expression of diabetic cells and
BVMs, it was necessary to identify potential genes that are expressed differently in
diabetic individuals that in non-diabetics.
A large variety of inflammatory markers has been shown to be up and/or down regulated
within a diabetic individual such as C-reactive protein (CRP), colony stimulating factors
(G-CSF, GM-CSF, M-CSF), interleukin-6 (IL-6), tissue factor (TF), vascular cell
adhesion molecule (VCAM), and intercellular adhesion molecule (ICAM) . Careful
56, 57

selection of genes of interest was required, as the BVM model is limited to ECs and
SMCs . As a result, genes were selected that had a limited interaction with immune
10-13

cells. Furthermore, genes were selected that had been shown to be affected by high
glucose concentrations. While the diabetic cells used in this thesis were not grown in high
glucose media, this is a future step that will be implemented and studied within the lab
for diabetic cell and BVM cultivation. Interleukin-6 and tissue factor were selected for
implementation in gene analysis of diabetic ECs and SMCs.
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3.3

METHODS

ECs and SMCs from either the umbilical vein and artery or coronary artery were
cultivated and expanded until enough cells were present for BVM cultivation. A detailed
cell culture protocol is provided in “Appendix I: CELL CULTURE & BVM
CULTIVATION PROTOCOLS.” Once enough cells had been expanded, they were
seeded onto an electrospun PLGA scaffold. The scaffold was 4-5cm in length and 3mm
inner diameter. The full BVM protocol can also be found in “Appendix I: CELL
CULTURE & BVM CULTIVATION PROTOCOLS.”
BVMs were placed in a bioreactor connected to an 8-roller pulsatile pump and placed in
an incubator for cultivation. There were three experimental groups employed for each
cell source; three BVMs were in each experimental group, resulting in 9 total BVMs for
each cell source. All 9 BVMs were cultivated and engineered using the same protocol
and then placed in the incubator at the same time point. After 1 day of cultivation three of
the BVMs were taken down and prepared for analysis. At this time point, a stent was
deployed in 3 of the 6 remaining BVMs and placed back into the incubator for an
additional 3 days. Upon harvesting each BVM, a portion of each sample was snap frozen
and placed in a -80°C for RNA isolation.
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As previously described in Chapter 2 and detailed in Appendix B through Appendix G:
qPCR DATA ANALYSIS PROTOCOL (SOP7106), RNA was isolated from BVMs and
flasks used to culture cells using QIAGEN’s RNeasy Mini Kit. The cell membranes were
lysed, lysed solution was washed with a series of buffers to isolate RNA, and eluted with
water. After quality assessments were performed and concentrations were obtained using
spectrophotometry, cDNA was reverse transcribed using iScript cDNA Synthesis Kit
(Bio-Rad). qPCR was performed by combining cDNA template, Fast SYBR Green
Master Mix, primers and water into appropriate wells.
Amplification plots and dissociation curves were analyzed for all samples and outliers
were identified and removed prior to data analysis. Threshold cycle values were obtained
from the resultant amplification plots and normalized to a reference gene. An equally
expressed reference gene was not identified for several of the sample groups being
compared, and, as a result, normalization was not performed within samples lacking a
suitable reference gene. The fold change was then calculated relative to a control sample.
The 1 day BVM set ups were used as a control for 3 day BVM set ups. The initial
passage number was used as a control to compare increasing passage number for cells.
3.3.1

Analysis of Reference Genes for Coronary and Umbilical Samples

A one-way ANOVA was performed on the following combinations of data to see if the
potential reference genes were expressed equally within all samples of interest.
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3.3.1.1 GAPDH Reference Gene Analysis
A one-way ANOVA was performed on the average cycle threshold cycles for GAPDH
on all umbilical and coronary BVM and control cell flasks. A significant difference was
present between the samples (p<0.0001). One-way ANOVA was subsequently performed
on the following groups of samples to see if any groupings of samples existed that did not
contain a significant difference in expression of ACTB: 1 day and 3 day coronary BVMs,
1 day and 3 day umbilical BVMs, and 1 day and 3 day coronary and umbilical BVMs.
Corresponding p-values for these groupings can be seen in “Table 3: One-way ANOVA
Results for GAPDH Expression in Various Sample Groups.”

66

Comparison of GAPDH Cycle Thresholds for Umbilical
and Coronary BVMs and Control Flasks
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Figure 20: Pictured above are cycle threshold values for GAPDH in all umbilical and
coronary BVMs and control cell flasks. A one-way ANOVA was performed; a significant
difference was present within the samples (p<0.0001).
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Table 3: One-way ANOVA Results for GAPDH Expression in Various Sample Groups

Samples Groups Compared

One-way ANOVA Results

All Umbilical & Coronary BVMs & Control Cell Flasks

p < 0.0001

1 Day & 3 Day Umbilical BVMs

No significant difference

1 Day & 3 Day Coronary BVMs

p < 0.00015

1 Day & 3 Day Umbilical & Coronary BVMs

p < 0.0001

3.3.1.2 ACTB Reference Gene Analysis
A one-way ANOVA was performed on the average cycle threshold cycles for ACTB for
all umbilical and coronary BVM and control cell flasks. A significant difference was
present between the samples (p<0.0001). One-way ANOVA was subsequently performed
on the following groups of samples to see if any groupings of samples existed that did not
contain a significant difference in expression of ACTB: 1 day and 3 day coronary BVMs,
1 day and 3 day umbilical BVMs, and 1 day and 3 day coronary and umbilical BVMs. A
significant difference was present in threshold cycle for all of the previously mentioned
groupings, corresponding p-values can be seen in Table 4: One-way ANOVA Results for
ACTB Expression in Various Sample Groups.
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Comparison of ACTB Cycle Thresholds for Umbilical
and Coronary BVMs and Control Flasks
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Figure 21: Pictured above are cycle threshold values for ACTB in all umbilical and
coronary BVM and cell flask samples. A one-way ANOVA was performed; a significant
difference was present within the samples (p<0.0001).

69

Table 4: One-way ANOVA Results for ACTB Expression in Various Sample Groups

Samples Groups Compared

One-way ANOVA Results

All Umbilical & Coronary BVMs & Control Cell Flasks

p < 0.0001

1 Day & 3 Day Umbilical BVMs

p < 0.0001

1 Day & 3 Day Coronary BVMs

p < 0.05

1 Day & 3 Day Umbilical & Coronary BVMs

p < 0.0001

3.3.1.3 Summary of Reference Gene Results for Nondiseased BVMs
An ideal reference gene was not identified for coronary and umbilical BVMs. Expression
of ACTB was shown to be significantly different between all sample groups analyzed.
The expression of GAPDH was significantly different in all sample groups, with the
exception of the 1 Day and 3 Day umbilical BVMs, in which no significant difference
was present.
As a result, GAPDH (Integrated DNA Technologies) was used for normalization between
all umbilical BVM samples; results for these samples are presented in the following
section, “3.4.1 Relative mRNA Abundance of 3 Day Umbilical Unstented and Stented
BVMs Compared to 1 Day Umbilical Unstented BVM.”
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Because an equally expressed reference gene was not identified for the remaining sample
groups, normalization was not performed for the results provided in the following
sections: “3.4.2 Relative Gene Expression of 3 Day Coronary Artery Unstented and
Stented BVMs to 1 Day Coronary Unstented BVM” and “3.4.4 Relative Gene Expression
of DHCAECs & DHCASMCs of Varying Passages Relative to Initial Passage.”
3.3.2

Analysis of Reference Genes for Diabetic Coronary Artery ECs & SMCs

HPRT1, RPS13 and ACTB were identified as potential reference genes. A one-way
ANOVA was performed on DHCAECs (passage 4 – passage 6) and DHCASMCs
(passages 6, 8 and 9) to see if the potential reference genes were expressed equally within
all samples of interest.
3.3.2.1 HPRT1 Reference Gene Analysis
A one-way ANOVA was performed on the average cycle threshold cycles for HPRT1 for
DHCAECs (p4 – p9) and DHCASMCs (p6, p8, p9). A significant difference was present
between the samples (p < 0.05). One-way ANOVA was subsequently performed on the
following groups of samples to see if any groupings of samples existed that did not
contain a significant difference in expression of HPRT1: DHCAECs (p4 – p9) and
DHCASMCs (p6, p8, p9). A significant difference was present within the DHCASMCs.
No significant difference was present within the DHCAECs. Corresponding p-values can
be seen in “Table 5: One-way ANOVA Results for HPRT1 Cycle Threshold Values in
DHCAECs & DHCASMCs.”
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Figure 22: Pictured above are cycle threshold values for HPRT1 expression in DHCAECs
(p4 – p9) and DHCASMCs (p6, p8, p9). A one-way ANOVA was performed; a
significant difference was present within the samples (p < 0.05).

Table 5: One-way ANOVA Results for HPRT1 Cycle Threshold Values in DHCAECs &
DHCASMCs

Samples Groups Compared

One-way ANOVA Results

DHCAECs (p4 – p9) & DHCASMCs (p6, p8, p9)
DHCAECs (p4 – p9)

p < 0.05
No significant difference

DHCASMCs (p6, p8, p9)

p < 0.05
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3.3.2.2 RPS13 Reference Gene Analysis
A one-way ANOVA was performed on the average cycle threshold cycles for RPS13 for
DHCAECs (p4 – p9) and DHCASMCs (p6, p8, p9). A significant difference was present
between the samples (p < 0.05). One-way ANOVA was subsequently performed on the
following groups of samples to see if any groupings of samples existed that did not
contain a significant difference in expression of RPS13: DHCAECs (p4 – p9) and
DHCASMCs (p6, p8, p9). No significant difference was present within both of these
sample groups. Corresponding p-values can be seen in “Table 6: One-way ANOVA
Results for RPS13 Cycle Threshold Values in DHCAECs & DHCASMCs.”
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Figure 23: Pictured above are cycle threshold values for RPS13 expression in DHCAECs
(p4 – p9) and DHCASMCs (p6, p8, p9). A one-way ANOVA was performed; a
significant difference was present within the samples (p < 0.05).
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Table 6: One-way ANOVA Results for RPS13 Cycle Threshold Values in DHCAECs &
DHCASMCs

Samples Groups Compared

One-way ANOVA Results

DHCAECs (p4 – p9) & DHCASMCs (p6, p8, p9)

p < 0.05

DHCAECs (p4 – p9)

No significant difference

DHCASMCs (p6, p8, p9)

No significant difference

3.3.2.3 ACTB Reference Gene Analysis
A one-way ANOVA was performed on the average cycle threshold cycles for ACTB for
DHCAECs (p4 – p9) and DHCASMCs (p6, p8, p9). A significant difference was present
between the samples (p < 0.0001). One-way ANOVA was subsequently performed on the
following groups of samples to see if any groupings of samples existed that did not
contain a significant difference in expression of ACTB: DHCAECs (p4 – p9) and
DHCASMCs (p6, p8, p9). A significant difference was present in threshold cycle for both
of the previously mentioned groupings, corresponding p-values can be seen in “Table 7:
One-way ANOVA Results for ACTB Cycle Threshold Values in DHCAECs &
DHCASMCs.”
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Figure 24: Pictured above are cycle threshold values for ACTB expression in DHCAECs
(p4 – p9) and DHCASMCs (p6, p8, p9). A one-way ANOVA was performed; a
significant difference was present within the samples (p < 0.0001).

Table 7: One-way ANOVA Results for ACTB Cycle Threshold Values in DHCAECs &
DHCASMCs

Samples Groups Compared

One-way ANOVA
Results

DHCAECs (p4 – p9) & DHCASMCs (p6, p8, p9)

p < 0.0001

DHCAECs (p4 – p9)

p < 0.0001

DHCASMCs (p6, p8, p9)

p < 0.0001
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3.3.2.4 Summary of Reference Gene Results for Diabetic Cells
None of the analyzed reference genes were expressed equally within both DHCAECs and
DHCASMCs. Both RPS13 and HPRT1 were expressed equally in DHCAECs (p4 – p9).
RPS13 was also expressed equally in DHCASMCs (p6, p8, p9). Expression of ACTB
was shown to be significantly different between all sample groups analyzed.
HPRT1 and RPS13 (Integrated DNA Technologies) were used for normalization of
DHCAECs and DHCASMCs, respectively. qPCR data analysis results are provided in
“3.4.4 Relative Gene Expression of DHCAECs & DHCASMCs of Varying Passages
Relative to Initial Passage.”
3.4
3.4.1

RESULTS
Relative mRNA Abundance of 3 Day Umbilical Unstented and Stented
BVMs Compared to 1 Day Umbilical Unstented BVM

Relative expression of PECAM, ICAM, SMA and BAX in 3 day unstented and stented
umbilical BVMs were analyzed with 1 day umbilical BVMs as the control. GAPDH
(Integrated DNA Technologies) was used for normalization between all umbilical BVM
samples. The goal of this comparison was to assess if any changes in gene expression
were induced by stent deployment in the BVM model. A visual representation of relative
mRNA abundance is provided in Figure 25. The fold change values with their standard
deviation are provided in
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.
All of the markers examined were down regulated in the 3 day unstented and 3 day
stented BVM in comparison to the 1 day BVM (endothelial cell marker, smooth muscle
cell marker, inflammation marker and apoptosis marker). A 2 tailed-t test was performed
on the means for each gene of interest; there were no significant differences present for
ICAM, SMA and BAX. There was a significant difference in relative mRNA expression
in PECAM (p < 0.000025).

Relative mRNA Abundance of 3 Day Umbilical BVMs
Compared to 1 Day Umbilical BVMs
Relative mRNA Abundance

2.0000
1.5000
1.0000
Unstented
Stented

0.5000
0.0000
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SMA

BAX

-0.5000
-1.0000

Figure 25: Relative mRNA Abundance in 3 Day Umbilical BVMs for PECAM, ICAM,
SMA and Ki67 is seen above. All genes were down regulated in comparison to the 1 day
umbilical control. Relative expression of PECAM was significantly different in the
unstented and stented comparison (p < 0.000025).
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Table 8: Fold Change Values for 3 Day Unstented & Stented Umbilical BVM Relative to
1 Day Stented Umbilical BVM

Fold Change Relative to 1 Day Umbilical BVM
Gene of Interest
PECAM

ICAM

SMA

BAX

Unstented Umbilical BVM

Stented Umbilical BVM

0.041

0.242

(0.0183 – 0.0920)

(0.131 – 0.449)

0.0099

0.0286

(0.00244 – 0.0397)

(0.0105 – 0.0777)

0.653

0.555

(0.270 – 1.576)

(0.167 – 1.848)

0.308

0.224

(0.076 – 1.254)

(0.186 – 0.270)
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3.4.2

Relative Gene Expression of 3 Day Coronary Artery Unstented and Stented
BVMs to 1 Day Coronary Unstented BVM

Relative expression of PECAM, ICAM, SMA, BAX and Ki67 in 3 day unstented and
stented coronary BVMs were analyzed with 1 day coronary BVMs as the control.
Normalization was not performed for the data provided in this section, as an equally
expressed reference gene was not identified for the samples compared within this section.
The goal of this comparison was to assess if any changes in gene expression were
induced by stent deployment in the BVM model. A visual representation of the relative
change in gene expression is provided in Figure 26. The fold change values are also
provided with their standard deviations in Table 9. A 2 tailed-t test was performed on the
means for each gene of interest to test for significant differences between the means.
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No significant differences were present between the unstented 3 day and stented 3 day
coronary BVM for the endothelial cell marker (PECAM) and the inflammation marker
(ICAM). Furthermore, both PECAM and ICAM were down regulated relative to the 1
day coronary BVM control. The smooth muscle cell marker (SMA) was up regulated in
the unstented 3 day coronary BVM and down regulated in the stented 3 day coronary
BVM relative to the 1 day coronary BVM control. There was a significant difference (p <
0.05) for SMA expression between unstented and stented coronary BVMs. The apoptosis
marker (BAX) was up regulated in the unstented 3 day coronary BVM and down
regulated in the stented 3 day coronary BVM; a significant difference was present in the
expression of BAX between the unstented and stented 3 day coronary BVM (p < 0.05).
The proliferation marker (Ki67) was up regulated in both 3 day coronary BVMs, with a
significant difference present (p < 0.05).
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Relative Gene Expression of 3 Day Coronary BVMs to
1 Day Coronary BVMs
Relative mRNA Abundance
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Figure 26: Pictured above is relative gene expression of 3 day coronary BVMs relative to
1 day BVMs. PECAM and ICAM were down regulated for both unstented and stented
BVMs. SMA and BAX were up regulated in the unstented coronary BVM and down
regulated in the stented coronary BVM. A statistical difference was present between the
unstented and stented coronary expression of SMA and BAX (p < 0.05). Ki67 was up
regulated in both unstented coronary and stented coronary BVMs, with a significant
difference present between both sample groups (p < 0.05).
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Table 9: Relative mRNA Expression for 3 Day Coronary BVMs

Fold Change Relative to 1 Day Coronary BVM
Gene of Interest
PECAM

ICAM

SMA

BAX

Ki67

3.4.3

Unstented Coronary BVM

Stented Coronary BVM

0.381

0.278

(0.159 – 0.603)

(-0.410 – 0.967)

0.781

0.4865

(0.103 – 1.460)

(-0.397 – 1.370)

2.456

0.527

(2.147 – 2.766)

(-0.958 – 2.008)

1.508

0.515

(0.895 – 2.120)

(-0.557 – 1.587)

4.547

1.482

(3.921 – 5.174)

(1.313 – 1.650)

Relative Gene Expression of Coronary BVMs to Umbilical BVMs

Normalization was not performed for the data provided in this section, as an equally
expressed reference gene was not identified for the samples compared within this section.
Relative expression of PECAM, ICAM, SMA and BAX was quantified between
umbilical and coronary BVMs. The goal of this comparison was to quantify differences
and/or similarities in gene expression induced in a BVM implementing cells from
different sources.
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PECAM, ICAM, SMA and BAX were all down regulated in the 1 day coronary BVM in
comparison to the 1 day umbilical model. PECAM expression was approximately
equivalent in the 3 day unstented coronary BVM in comparison to the 3 day unstented
umbilical BVM. Similar to the 1 day BVMS, SMA and BAX remained to be down
regulated in the 3 day unstented coronary BVM in comparison to the 3 day unstented
umbilical BVM. There was a large up regulation of ICAM in the 3 day unstented
coronary BVM relative to the 3 day unstented umbilical BVM. PECAM and SMA were
both down regulated in the 3 day stented coronary BVM in comparison to the 3 day
stented umbilical BVM. ICAM and BAX were both up regulated in the 3 day stented
coronary BVM relative to the 3 day stented umbilical BVM.
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Relative Gene Expression of Coronary BVMs to
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Figure 27: Relative expression of PECAM, ICAM, SMA, and BAX for coronary BVMs
relative to the corresponding umbilical BVM model is seen above. There was a slight
down regulation of all markers in the 1 day coronary BVM. PECAM expression
remained relatively equivalent in the 3 day unstented coronary BVM, with a down
regulation in SMA and BAX, and an up regulation in ICAM. A relative down regulation
was present in PECAM and SMA expression in the 3 day stented coronary BVM with an
up regulation in ICAM and BAX.
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Table 10: Relative mRNA for Coronary BVMs Relative to Umbilical BVMs

Fold Change Relative to Corresponding Umbilical BVM
Gene of Interest
PECAM

ICAM

SMA

BAX

3.4.4

1 Day Unstented
Coronary

3 Day Unstented
Coronary BVM

3 Day Stented
Coronary

0.115

1.142

0.142

(-0.859 – 1.089)

(0.920 – 1.365)

(-0.546 – 0.831)

0.365

30.97

6.683

(-0.089 – 0.819)

(30.288 – 31.646)

(5.799 – 7.567)

0.043

0.172

0.067

(-0.549 – 0.634)

(-0.137 – 0.482)

(-1.413 – 1.547)

0.683

0.340

1.691

(0.063 – 1.303)

(-0.273 – 0.952)

(0.618 – 2.763)

Relative Gene Expression of DHCAECs & DHCASMCs of Varying Passages
Relative to Initial Passage

Relative expression of IL-6, TF, ICAM, PECAM, SMA, BAX and Ki67 in DHCASMCs
(p8 and p9) and DHCAECs (p5 – p9) was analyzed with DHCASMCs (p5) and
DHCAECs (p4) as their controls, respectively. RPS13 was used for normalization
between DHCASMCs and HPRT1 was used for normalization between DHCAECs. The
goal of both of these comparisons was to assess potential changes in gene expression in
DHCASMCs and DHCAECs as they age and increase in passage number.
Relative mRNA abundance of previously listed markers of DHCASMCs can be seen in
Figure 28. Values obtained for relative mRNA abundance are also listed in Table 11.
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The following marker’s expression remained relatively constant for DHCASMCs of
passage 8 and 9 relative to passage 4: diabetic inflammation marker (IL-6), endothelial
cell marker (PECAM), smooth muscle cell marker (SMC), apoptosis marker (BAX) and
proliferation marker (Ki67). Tissue factor was down regulated in both passages 8 and 9
relative to passage 4. The inflammatory marker (ICAM) was up regulated in both passage
8 and 9 relative to passage 4.
Relative mRNA abundance of previously listed markers of DHCAECs can be seen in
Table 12, Figure 29 and Figure 30. IL-6 and TF were both slightly up regulated for
DHCAECs for all passages relative to passage 4. ICAM expression was slightly up
regulated at passage 5, then down regulated for passage 6, and then remained fairly
constant for subsequent passages. The relative expression of PECAM, BAX and Ki67
were all slightly down regulated in subsequent passages, and remained fairly constant for
subsequent passages. SMA initially experienced an increase in expression, which was
subsequently reduced and followed by a relatively equal expression to that seen in
passage 4.
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Figure 28: Relative mRNA abundance of IL-6, TF, ICAM, PECAM, SMA, BAX and
Ki67 for DHCASMCs with DHCASMCs p4 as their control. Most of the marker’s
expression remained relatively constant, with the exception of TF (which was down
regulated) and ICAM (which was up regulated).
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Table 11: Relative mRNA Abundance for DHCASMCs

mRNA Abundance Relative to DHCASMCs at Passage 4
Gene of Interest
IL-6

TF

ICAM

PECAM

SMA

BAX

Ki67

DHCASMC (Passage 8)

DHCASMC (Passage 9)

0.956

0.913

(0.349 – 1.562)

(0.616 – 1.210)

0.297

0.207

(-0.064 – 0.657)

(-0.029 – 0.443)

12.86

2.919

(12.45 – 13.27)

(2.528 – 3.309)

0.460

1.145

(0.143 – 0.777)

(0.971 – 1.319)

2.049

0.686

(1.428 – 2.670)

(-0.089 – 1.461)

0.920

0.327

(0.593 – 1.247)

(0.136 – 0.518)

0.539

1.236

(0.196 – 0.883)

(0.795 – 1.676)

88

Expression of DHCASMCs (p5 - p9) Relative to
DHCASMC (p4)
Relative mRNA Abundance
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Figure 29: Relative mRNA abundance of IL-6, TF and ICAM for DHCAECs (p5 – p9)
with p4 DHCAECs as their control. IL-6 and TF were slightly up regulated for all
passages. IL-6 experienced an extremely large up regulation in expression at passage 9.
ICAM expression experienced a slight up regulation at passage 5 and then was down
regulated for all subsequent passages and remained fairly constant.
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Figure 30: Relative mRNA abundance of PECAM, SMA, BAX and Ki67 for DHCAECs
(p5 – p9) with p4 DHCAECs as their control. The relative expression of PECAM, BAX
and Ki67 were all slightly down regulated in subsequent passages, and then remained
fairly constant. SMA initially experienced an increase in expression ,which was
subsequently reduced and followed by expression that was relatively equal to that seen in
passage 4.
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Table 12: Relative RNA Abundance for DHCAECs

mRNA Abundance Relative to DHCAECs at Passage 4
Gene of
Interest

IL-6

TF

ICAM

PECAM

SMA

BAX

Ki67

DHCAECS
(Passage 5)

DHCAECS
(Passage 6)

DHCAECS
(Passage 7)

DHCAECS
(Passage 8)

DHCAECS
(Passage 9)

2.424

1.933

1.374

0.555

63.734

(1.894 –
2.954)

(1.228 –
2.639

(0.4666 –
2.282)

(0.088 –
1.023)

(63.1888 –
64.280)

7.904

1.522

2.438

1.385

1.489

(7.464 –
8.344)

(0.767 –
2.278)

(1.454 –
3.422)

(1.080 –
1.689)

(1.021 –
1.956)

1.914

0.760

0.406

0.130

0.569

(1.397 –
2.432)

(0.102 –
1.419)

( -0.400 –
1.213)

(-0.074 –
0.334)

(0.285 –
0.854)

0.366

0.096

0.102

0.062

0.068

(0.302 –
0.429)

(-0.521 –
0.713)

(-0.697 –
0.901)

(-0.117 –
0.241)

(-0.018 –
0.154)

2.870

1.097

0.990

1.017

0.759

(2.467 –
3.273)

(0.423 –
1.771)

(0.286 –
1.747)

(0.286 –
1.747)

(0.425 –
1.093)

1.256

0.543

0.467

0.204

0.263

(1.153 –
1.359)

(-0.083 –
1.168)

(-0.223 –
1.157)

(-0.009 –
0.204)

(0.154 –
0.372)

0.153

0.063

0.057

0.021

0.030

(-0.332 –
0.638)

-0.577 –
0.704)

(-0.810 –
0.923)

(-0.536 –
0.578)

(-0.392 –
0.453)
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3.5

Discussion & Conclusion

The following sections will review the changes present in gene expression induced by
stent deployment in the umbilical and coronary BVMs, the differences present in gene
expression in the coronary BVMs relative to the umbilical BVMs, and gene expression
results in diabetic cells. A brief discussion of the limitations of the results presented here
and a comparison of the results to what had previously been seen in our lab will also be
provided.
3.5.1

Gene Expression Changes Induced by Stent Deployment

In the umbilical BVM, no changes were induced in the inflammation marker (ICAM),
smooth muscle cell marker (SMA) or apoptosis marker (BAX) by stent deployment. A
significant difference was present in the expression of the endothelial cell marker
(PECAM) in the stented umbilical BVM in comparison to the unstented 3 day umbilical
BVM; an increase in the down regulation present in the 3 day unstented BVM was
further down regulated after stent deployment.
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In the coronary BVM, no changes were induced in the endothelial cell marker (PECAM)
and the inflammation marker (ICAM) by stent deployment. A significant difference was
present in expression of the smooth muscle cell marker (SMA), apoptosis marker (BAX)
and proliferation marker (Ki67) in the responses induced after stenting. The smooth
muscle cell marker (SMA), which had previously been up regulated in the unstented 3
day coronary BVM, was down regulated in the stented coronary BVM. Both the
proliferation marker (BAX) and apoptosis marker (Ki67), which had been up regulated in
the 3 day unstented coronary BVM, were down regulated in the stented coronary BVM.
3.5.2

Comparison of Gene Expression in Umbilical and Coronary BVMs

Overall, the coronary BVMs experienced a slight down regulation in all markers in
comparison to their corresponding umbilical BVMs, with the exception of the
inflammation marker (ICAM) and the apoptosis marker (BAX). The inflammation maker
(ICAM) experienced a large up regulation in both unstented and stented 3 day coronary
BVMs relative to the corresponding umbilical BVMs. The apoptosis marker (BAX) was
slightly up regulated in the stented coronary BVM relative to the stented umbilical BVM.

93

3.5.3

Aging of Diabetic Cells

Slight fluctuations were present in both the DHCASMCs and DHCAECs as they
increased in passage number, however significant trends in up or down regulation was
not present as the passage number increased. The DHCASMCs experienced a relatively
large up regulation in the inflammation marker (ICAM) with increased passage numbers.
The two factors identified as potential markers for diabetes, interleukin-6 (IL-6) and
tissue factor (TF), were both up regulated in all subsequent passages relative to initial
passage 4. There was a very large increase present in passage 9 of IL-6, with a fold
change of 63.7. IL-6 is a pro-inflammatory marker. The up regulation in ICAM and IL-6
suggests an increase in inflammation in DHCAECs as their passage number increases.
3.5.4

Limitations

A limitation to the results provided is the lack of results on the proliferation marker in
umbilical BVMs. Due to limited sample availability, there wasn’t enough cDNA or RNA
for the umbilical BVMs (this is discussed more thoroughly in “Appendix A: LIST OF
EQUIPMENT MALFUNCTIONS & UNFORESEEN DIFFICULTIES”).
Additionally, gene expression was not performed on DHCASMCs from passage 6 or 7
due to contamination of the cell flasks prior to harvesting.
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The lack of a suitable reference gene for comparison between coronary BVMs and
between coronary and umbilical BVMs was also a limitation. However, the lack of a
suitable gene was due to limited sample availability, rather than due to extensive testing
of suitable reference genes. Only GAPDH and ACTB could be tested as potential
reference genes, as there wasn’t enough cDNA or RNA to perform additional qPCR runs.
Therefore, there is still the potential of identifying a suitable reference gene to be used for
these applications.
Furthermore, while a reference gene was identified for diabetic ECs and SMCs
individually, a reference gene was not identified for usage between these cell types.
While this did not affect the results presented in this thesis, as a comparison between
these cell types was not desired, it is not desirable for the reference gene to be expressed
differently in both cell types that are intended to be implemented in a BVM.
3.5.5

Comparison to Results Previously Obtained in the Lab

Michael and Sarah had previously performed qPCR on umbilical BVMs within the lab,
however a comparison to their results was unable to be made due to the lack of a suitable,
comparable control within their experiment. They used both ECs and SMCs as a control
for BVM analysis, which cannot be compared to the results obtained in this thesis .
10

95

Sarah performed an additional qPCR experiment in which she compared 1 day umbilical
and coronary BVMs . Sarah’s findings differed from those presented in this thesis as
13

Sarah found a down regulation of PECAM, ICAM and BAX was present in umbilical
BVMs relative to coronary BVMs . A down regulation was present in these same
13

markers (PECAM, ICAM, and BAX) for coronary BVMs relative to umbilical BVMs in
the results presented in this thesis.
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Chapter 4. DISCUSSION AND CONCLUSION

4.1

SUMMARY OF THE THESIS

The following methods were optimized and documented in standard operating
procedures: RNA isolation, RNA quality assessments, cDNA synthesis, qPCR methods
and qPCR data analysis. These optimized methods were then applied to stented and
unstented umbilical and coronary BVMs and diabetic human coronary artery smooth
muscle cells and endothelial cells.
4.1.1

Aims

The first aim of this thesis was to optimize existing qPCR protocols to ensure that valid
results were obtained. RNA isolation protocols were modified to increase the purity and
concentration of isolated RNA, and Agarose gel electrophoresis was implemented in the
lab to further evaluate RNA quality and purity. Usage of dissociation curves was
implemented in the qPCR protocol in order to verify that DNA segments (or amplicons)
produced in the qPCR reaction were all of the targeted DNA sequence. qPCR data
analysis protocols were enhanced to include analysis of potential reference genes, and to
identify and remove outliers within qPCR results. These optimized protocols were
thoroughly documented in standard operating procedure documents, which are provided
in Appendices B through G.
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The second aim of this thesis was to apply the optimized protocols to 1 day unstented, 3
day stented and 3 day unstented coronary and umbilical BVMs and diabetics coronary
artery ECs and SMSs. Relative gene expression was compared within each coronary and
umbilical model to assess the BVM response to stent deployment. Gene expression was
also compared between 1 day unstented, 3 day unstented and 3 day stented coronary and
umbilical BVMs to assess differences and similarities between the BVMs created from
different cell sources. Lastly, gene expression was analyzed on increasing passage
numbers of DHCAECs and DHCASMCs to quantify potential changes in gene
expression as the cells age.
4.1.2

Results

In umbilical BVMs, there was a down regulation of the endothelial cell marker (PECAM)
after stent deployment. No other changes were induced by stent deployment in the
umbilical model. In coronary BVMs, the smooth muscle cell marker (SMA) was down
regulated and the proliferation marker (Ki67) and apoptosis marker (BAX) were both up
regulated after stent deployment. No other changes were induced by stent deployment in
the coronary model.
The endothelial cell marker (PECAM) and the smooth muscle cell marker (SMA) were
both slightly down regulated in the coronary BVM models in comparison to the umbilical
BVM models. Coronary BVMs also experience an up regulation in the inflammation
marker (ICAM) and the apoptosis marker (BAX) in comparison to the umbilical BVMs.
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No significant trends were seen in increasing passage numbers of DHCASMCs and
DHCAECs, with the exception of the inflammation and potential diabetic marker, IL-6,
which was up regulated in passage 9.
4.2

IN CONTEXT WITH WORK OF OTHERS

Punchard et al previously used qPCR to analyze relative gene expression in a tissue
engineered blood vessel (TEBV) similar to the BVMs analyzed in this thesis . They
26

deployed a stent into a TEBV that contained HUVECs on a fibronectin coated silicone
scaffold and analyzed gene expression after 24 hours of cultivation with the stent in
place . They characterized the expression of inflammation markers (E-selectin, ICAM,
26

VCAM) after stent deployment. They found an up regulation in inflammatory markers in
the stented TEBV, which is similar to the in vivo response . This differs from our results,
26

as we did not see a significant change in expression of the inflammatory marker (ICAM)
in our stented BVMs when compared to their unstented BVMs. This is surprising, as stent
deployment causes an inflammatory response.
4.3

LIMITATIONS

The following sections will provide a discussion on the following limitations that were
presented in this thesis: non-optimal dissociation curves for GAPDH and TF, lack of a
suitable reference gene, the loss of diabetic BVMs and the lack of hyperglycemia
conditions in diabetic cell culture.
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4.3.1

Dissociation Curves

GAPDH and TF both had dissociation curves that contained a second, small curve, which
can be seen in Figure 37 and Figure 58 of “Appendix L: DISSOCIATION CURVES
AND AMPLIFICATION PLOTS.” Furthermore, there was amplification present at a
very late cycle in the non template control for GAPDH, which can be seen in Figure 36 of
“Appendix L: DISSOCIATION CURVES AND AMPLIFICATION PLOTS.” In future
work, gel electrophoresis should be ran on qPCR amplicon products in conjunction with a
DNA ladder to confirm whether or not primer-dimer formation is occurring. If primerdimer formation is occurring it will be necessary to purchase new forward and reverse
primers.
4.3.2

Lack of a Suitable Reference Gene

Some of the data presented in this thesis was analyzed without the usage of a reference
gene. As previously mentioned, reference genes have been required to normalize PCR
results to account for loss when transcribing complementary DNA from the isolated
RNA. Methods have improved tremendously, drastically reducing the amount of RNA
that is lost during DNA transcription. As a result, qPCR analysis was carried out even
though an ideal reference gene had not been identified. It is not ideal, however, to analyze
qPCR without normalization to a reference gene.
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4.3.3

Loss of Diabetic BVMs

The analysis of diabetic BVMs was originally intended to be included in this thesis.
However, the diabetic BVMs were stored in a -80°C that malfunctioned prior to RNA
isolation of the BVMs (as listed in “Appendix A: LIST OF EQUIPMENT
MALFUNCTIONS & UNFORESEEN DIFFICULTIES”). The diabetic BVMs were left
at room temperature for several days and were not able to be used for qPCR analysis.
Due to time constraints and the long culture time required to expand DHCASMCs,
diabetic BVMs were not included in this thesis.
4.3.4

Lack of Hyperglycemic Conditions in Diabetic Cell Culture

Hyperglycemic conditions were not used within this thesis, which is seen in many
diabetic individuals. Evaluation of the DHCASMCs and DHCAECs were intended to be
used as a baseline for future lab experiments in which hyperglycemic conditions are
implemented.
4.4

FUTURE WORK

Future steps include testing new reference genes, testing diabetic primers on diabetic
BVMs, and growing diabetic blood cells and BVMs in high glucose media.
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Additional reference genes should be tested within the lab, ultimately with the goal to
establish several genes that are expressed equally within all cell types and cell sources
utilized. Due to many difficulties encountered throughout this thesis, RNA volumes were
extremely limited and did not permit for an examination of all reference genes. As a
result, expression of reference genes that are currently in lab inventory should first be
assessed for 1 day unstented, 3 day unstented and 3 day stented coronary, umbilical, and
diabetic coronary BVMs.
If BVMs are not available for reference gene analysis, qPCR can be conducted on EC and
SMCs prior to BVM analysis. A reference gene that is expressed equally in both cell
types in cell culture may not be equally expressed in BVMs due to cell interactions with
each other, the PLGA scaffold and stent deployment. However, equal expression of a
reference gene in both cell types in cell culture may reduce change of a significant
difference being expressed in BVMs.
Additional reference genes such as ribosomal proteins should be assessed. Selection of
actins and tubulins are not recommended as potential reference genes due to the high
variation seen in ACTB expression in all samples assessed in this thesis. Furthermore, it
is highly likely that stent deployment may cause variations in cell structure proteins such
as these.
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Future analysis should be performed on healthy and diseased BVMs to assess similarities
and differences in relative gene expression of the models. Initial comparisons can be
made by directly comparing HCAECs to DHCAECs and HCASMCs to DHCASMCs to
assess changes in expression of inflammatory, proliferative, and apoptosis markers.
Furthermore, tissue factor and interleukin-6 expression should be characterized in a
diabetic BVM. Lastly, diabetic cells should be cultured in high glucose media to mimic a
hyperglycemic environment.
4.5

OVERALL CONCLUSION

Overall, protocols for RNA isolation, cDNA synthesis, qPCR methods and data analysis
were modified and optimized to create reproducible and valid results. qPCR standard
operations of procedures were created for each of these protocols. Optimized qPCR
protocols were successfully implemented in order to compare relative gene expression
between 1 day unstented, 3 day unstented, and 3 day stented coronary and umbilical
BVMs, and DHCAECs and DHCASMCs of varying passage number. Results were used
to assess the response of coronary and umbilical BVMs to stent deployment, the
differences and similarities between BVMs from different sources, and to characterize
changes in gene expression of DHCAECs and DHCASMCs as the cells age.
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APPENDICES
Appendix A: LIST OF EQUIPMENT MALFUNCTIONS & UNFORESEEN
DIFFICULTIES
•

C1000 Touch Thermal Cycler (Bio-Rad) malfunctioned. The thermal cycler had
already begun running when the error message appeared. As a result, qPCR was
carried out to identify whether cDNA synthesis was effectively performed.
Unfortunately, cDNA was not effectively executed and these samples (coronary
and umbilical samples) were discarded. An alternate thermal cycler was used in
Dr. Peterson’s lab for all future experiments.

•

We had been using 96-well PCR plates and SYBR green for regular speed qPCR.
We should have been using 96-well PCR plates and fast SYBR green for fast
qPCR. The 96-well plates have thinner plastics to allow the sample to heat and
cool more efficiently/quickly.

•

Old and/or contaminated primers. Primers had been thawed an unknown amount
of times and most had been in stock 3-4 years since their first use. These primers
were discarded and all new primers were purchased. New primers were separated
into several working solutions to minimize the amount of times each forward and
reverse primer was thawed.

•

A portion of the 3 day umbilical samples had been previously used, on a plate that
did not produce valid results. Furthermore, the cDNA tubes containing these
samples were accidently spilled during the final BAX plate run. As a result, not
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all of the samples were ran on the BAX run (as there wasn’t enough cDNA), and
there was not enough sample to use for the Ki67 plate.
•

Diabetic smooth muscles cells (passages 6 and 7) were contaminated during cell
culture. As a result, gene expression analysis was not performed on these
passages.

•

Storage of RNA (coronary and umbilical samples only) had initially been in a 20°C freezer for 6 – 8 weeks and then transferred to an -80º C freezer. Gel
electrophoresis was performed on these samples to confirm RNA integrity, and
then promptly stored in a -80º C freezer.

•

The -80 freezer broke. RNA samples and biological samples (diabetic stented and
unstented BVMs) were left at room temperature for an unknown amount of time
(probably around 1 week). Gel electrophoresis was performed on the gel samples
to ensure their quality. The biological samples were discarded.

•

The water used for some of the qPCR plate runs may have been contaminated.
New water was used as well as new primers to eliminate any potential
complications.
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Appendix B: RNA ISOLATION PROTOCOL (SOP7100)

SOP7100
REV B
Page 1 of 3
RNA Isolation
Purpose: to isolate RNA from a BVM and/or a cell flask
Approx. Time:
Procedure:
1 hour
A. Preparation
1. Wash hands and put on gloves
Abbreviations:
2. Spray down working area with 18Ω H20
BVM – blood
3. Wipe down working area and micropipettes with
vessel mimic
Rnase Zap Wipes
4. Obtain and label (sample name/number)
Reminders:
QIAshredder, RNeasy Spin Column and 2 RNase free
1. Balance
collection tubes (1.5 mL) for each sample
centrifuge prior
4.1. Final sample will be stored in 1 of the collection
to each use!
tubes
2. BVMs are
4.1.1. Label should include initials, date, sample
submerged in
name and sample type (RNA)
liquid nitrogen
and stored in a
B. Sample Preparation – Cell Flasks
-80°C freezer
once harvested. Performed in TE Lab:
1. Spray down hood with 70% IPA
3. Maximum
2. Warm up the exact quantity of media needed in small
binding
conical (amount needed to deactivate Trypsin)
capacity of
3. Trypsinize cells
RNA for
3.1. Aspirate media from flask
RNEasy Mini
3.2. Water fall DCF-PBS and rinse
Kit is 100 ug.
3.3. Aspirate DCF-PBS
3.4. Add Trypsin (1 mL for T25, 3 mL for T75 & 9
mL for T225)
3.5. Incubate for several minutes
3.6. Check on cells, pound to remove from flask
3.7. Deactivate with media (3:1 ration of media to
trypsin for human cells sources)
4. Label new conicals with sample names
5. Transfer cell solution from flask to corresponding
conical
6. Centrifuge conicals with cell solution for 4 min at
setting #4
7. Aspirate solution above cell pellet
8. Add approximately 5 mL DCF-PBS to cell pellet
9. Re-suspend cell pellet by pipetting up and down
10. Repeat steps 6 & 7
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Materials:
1. RNEasy Mini
Kit (Qiagen)
" RNeasy
Spin
Column
" 1.5 & 2.0
mL
Collection
Tubes
" Buffer RLT
" Buffer RPE
" RW1
Washing
Buffer
" Collection
Tubes
" RNase Free
Water
2. 70% Ethanol
3. 18Ω H20
4. DCF-PBS
5. Trypsin & cell
media (if
harvesting
cells)
6. RNase Zap
Wipes
7. QIAshredder
Spin Columns
8. Sterile pipet
tips
9. Waste beaker

11. Submerge conical containing cell pellet in liquid
nitrogen for approximately 15 seconds
12. Move cell pellet in conical to Bonderson lab
C. Sample Preparation – BVMs
1. Record approximate dimensions of BVM(s)
2. Inspect sample for residual media
2.1. If residual media is present, add enough DCFPBS to submerge the BVM
2.2. Pipette up and down to mix until BVM has lost its
pinkish tint
2.3. Transfer BVM to 1.5 mL collection tube
D. RNA Isolation – All Sample Types
1. Add appropriate amount of Buffer RLT to BVM in
1.5 mL collection tube (see Table 1: Volume of
Buffer RLT Required)
Table 1: Volume of Buffer RLT Required
Volume Buffer RLT
Approximate Cell Count
(uL)
350
100 < 5x106
600
5x106 – 1x107
1.1. Pipette up and down to mix
1.2. Vortex tube for 2 mins
NOTE: For stented BVMs, make e sure stent is left in
BVM tube when applying Buffer RLT.
2. Transfer all cell lysate to QIAshredder Spin Column
for homogenization
2.1. Centrifuge at 161000 rcf for 2 mins
3. Add equal volume of 70% Ethanol as Buffer RLT to
cell lysate flow
3.1. Pipette up and down thoroughly to mix
4. Transfer 600 uL flow through solution to RNeasy
Spin Column
4.1. Centrifuge at 161000 rcf for 15 secs
4.2. Discard flow through in waste beaker
5. Repeat step 3 for remaining flow through from
QIAshredder Spin Column collection tube to RNeasy
Spin Column
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6. Add 700 uL RW1 Washing Buffer to RNeasy spin
column
6.1. Centrifuge at 161000 rcf for 15 secs
6.2. Discard flow through in waste beaker
7. Add 500 uL Buffer RPE To RNeasy spin column
7.1. Centrifuge at 161000 rcf for 15 sec
7.2. Discard flow through in waste beaker
8. Add 500 uL Buffer RPE To RNeasy spin column
8.1. Let sit for 5 minutes
8.2. Centrifuge at 161000 rcf for 2 min
8.3. Discard flow through in waste beaker
9. Centrifuge empty RNeasy spin column for 2 min
10. Change gloves
11. Place spin column in new 1.5 mL collection tube
12. Add 30 – 100 uL Buffer water into spin column (Can
use less to increase concentration if you think you
have a low cell count)
12.1. Centrifuge at 161000 rcf for 1 min
12.2. RNase free water from the kit may be used as
buffer water
13. Add the same volume of Buffer water as used in step
12 to the top of RNeasy spin column
13.1. Centrifuge at 161000 rcf for 1 min
14. Throw RNeasy spin column in biohazard; RNA
should be in flow through in collection tube
15. See SOP for RNA Quality Assessments for protocols
on Gel Electrophoresis and Spectrophotometry
16. Store RNA in -80°C freezer once all quality
assessments are complete
D. Clean Up
1. Discard waste beaker contents in sink; clean waste
beaker
2. Discard spin columns, collection tubes and pipette
tips in biohazard
3. Put away supplies and reagents
4. Spray down working area with 70% IPA
Revision History
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Michael Gibbons
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Appendix C: RNA QUALITY ASSESSMENTS PROTOCOL (SOP 7102)

QS7102
REV B
Page 1 of 2
RNA Quality Assessments
Purpose: to assess the quality of isolated RNA through spectrophotometry and gel electrophoresis
Approx. Time: Procedure:
❶ Pictures
1 hour
Abbreviations: A. Spectrophotometry
1. Open NanoDrop 2000 program on laptop
1. EtBr
2. Select Nucleic Acid
(Ethidium
3. Perform wavelength verification
Bromide)
3.1. Lower arm
2. TAE (Tris4. On Type select RNA (DNA should be default)
acetate5. Rinse stage with RNase free water (or whatever buffer
EDTA)
was used to dilute RNA sample)
Reminders:
6. Blank Spectrophotometer
1. Remove
6.1. Add 1 uL RNAse free water to stage
gloves when
6.2. Lower arm and blank spectrophotometer
using
7. Dry stage with kim wipe
NanoDrop
8. Name sample (initials, sample ID, date)
computer in
9. Flick RNA sample to mix
Bonderson
10. Apply 1 uL to stage
2. Make sure to
11. Click Measure
mark
11.1. Record the concentration, 260/280 and 260/230
orientation of
measurements
your samples
12. Leave kim wipe under arm when done
in electrophoresis tray!
B. Gel Electrophoresis
Materials:
1. Measure 50 mL TAE
1. Agarose
2. Weigh 0.5g Agarose on parafilm paper or in weigh
2. TAE
boat
3. EtBr
3. Add Agarose to TAE and microwave until Agarose
4. Flask &
has dissolved
Graduated
3.1. Stop and swirl so that solution doesn’t boil over
Cylinder
4. Add 2 uL of EtBr to TAE & Agarose solution
5. RNase free
5. Let TAE & Agarose solution cool
water
5.1. A good rule of thumb is until you are able to hold
6. Kim Wipes
your palm to flask for 10 seconds
7. Loading Dye
6. Tape sides of electrophoresis tray so that gel can
8. Buffer Water
harden in tray
9. Parafilm
7. Pour TAE EtBr solution into tray
7.1. Wait until TAE EtBr polymerizes
Equipment:
8. Mix sample and loading dye on a sheet of parafilm
1. Electro8.1. 2-5 uL sample + 2 uL loading dye
phoresis
9. Pipet samples into gel wells
Equipment
10. Place electrophoresis tray into electrophoresis
machine
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UV Machine
& attached
camera
3. Scale
2.

11. Use TAE to fill machine
11.1. Pour enough to cover the electrophoresis tray
12. Run at 125 V for 30 minutes
13. Turn off electrophoresis machine
14. Remove electrophoresis tray from electrophoresis set
up and dry with a paper towel

C. Obtaining Image
1. Turn on camera, UV machine and computer
2. Place electrophoresis tray in UV machine
3. Take image using filter #3 on UV machine
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Appendix D: REVERSE TRANSCRIPTION PROTOCOL (SOP7103)

SOP7103
REV B
Page 1 of 1
Reverse Transcription
Purpose: to perform reverse transcription
Approx. Time: Procedure:
1 hour (depends
on sample size, A. Preparation
estimate based
1. Calculate amount RNA needed
on 10 samples)
1.1. (1000 ng)*(1 mL/[RNA ng/nL]) = Volume (RNA)
Abbreviations: 2. Calculate amount H2O needed
2.1. 15 uL – Volume (RNA) = Volume (H20)
RT = Reverse
transcriptase
3. Wipe working area & micropipettes with 18Ω H20.
Tube =
with RNase Zap Wipes.
Nuclease free
tube
B. RNA Isolation
Reminders:
1. Prepare master mix
1. Include 10%
1.1. Multiply amounts of each component by number
for pipetting
of samples
errors
1.1.1. Include additional 10% (to account for
2. Store iScript
pipetting errors)
cDNA
1.1.2. 4 uL 5X iScript Reaction Mix per reaction
Synthesis Kit
1.1.3. 1 uL RT per reaction
at -20°C
2. Put 5 uL master mix in each Nuclease free tube
Materials:
3. Add appropriate amount of H2O and RNA to each
1. iScript cDNA
tube (dependent on sample)
Synthesis Kit
4. Centrifuge briefly (a few seconds)
(BIORAD)
5. Load samples into thermal cycler and run below
! iScript
program making sure the lid to the thermal cycler is
Reaction
securely touching the tops of your tubes
Mix
5.1. Ensure you place cDNA tubes in the correct holes
! RT Mix
(there are larger and smaller holes). Your tube should
! RNase
go in the smallest one it fits into.
Free Water
5.2. 25°C for 5 min (300 sec)
2. Nuclease free
5.3. 42°C for 30 min (1800 sec)
tubes
5.4. 85°C for 5 min (300 sec)
Equipment
- Thermal
Cycler
- Centrifuge

5.5. 4°C forever
5.6. Total sample volume = 20 uL
6. Dilute cDNA 1:5 with 80 uL 18Ω H2O or RNase free
water
7. Store cDNA at -20°C
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Appendix E: PRIMER DESIGN PROTOCOL (SOP7104)

SOP7104
REV B
Page 1 of 3
Primer Design
Purpose: to design forward and reverse primers.
Approx. Time: Procedure:
Dependent on
amount of
A. Obtaining Gene Sequence for Gene of Interest
primers
1. Go to GenBank (http://www.ncbi.nlm.nih.gov/genbank/) !
Abbreviations:
2. Select Nucleotide from the drop down menu !
Reminders:

3. Search for the gene of interest, ensuring that the human
protein (Homo sapiens) is selected !
4. Ensure that mRNA is selected !
5. Scroll to the bottom of the page to locate the sequence !
6. Record the accession number and copy the gene sequence
a. It is beneficial to select an mRNA sequence that
spans an intron in the DNA sequence (to prevent
amplification of contaminated DNA in qPCR
reaction)
7. Go to PrimerQuest
(http://www.idtdna.com/primerquest/home/index)

Materials:
1. A Computer
with Internet
Access
2. Forward &
Reverse Lab
Ready Primers
3. Buffer
(Nuclease
Free Water)

8. Copy the sequence into the box at the top of the page that says
“Sequence Entry” (it will automatically ignore the line
!numbers) !
9. Input the sequence name
10. Select “Show Custom Design Parameters”
a.

One the right hand side select “qPCR intercalating
Dyes (Primers Only)”

b.

Set “Primer Size (nt)” Min to 18, Optimum to 20, and
Max to 22 !

c.

Set “Primer Tm” Min to 59.0, Optimum to 60.0, and
Max to 61.0 !

d.

Set “Amplicon Size (bp)” to Min to 180, Optimum to
200, and Max to 220 !

e.

You may leave all other parameters as is
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Primer Design

f.

11.

Click “Get Assays.” PrimerQuest will out put 5 sets of
forward and reverse primers that match input
criteria. Perform the remaining steps until you
have selected an optimal primer set. Being by
selecting “View Assay Details” for the first
primer set. This will take you to a new page that
provides you with the forward and reverse
primers. Copy these sequences.
Go to NetPrimer (leaving the IDT page open)

http://www.premierbiosoft.com/NetPrimer/AnalyzePrimer.jsp
12.

Input copied forward and reverse primers, name of
sequence and a description

13.

Click “Analyze”

14.

Analyze “Rating” (Ideal rating is around 95% and higher
for each primer, however it is okay if this is not possible
for the selected gene

15.

Once a primer set with optimal ratings has been
determined, go to Primer-BLAST
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) !

16.

Enter the selected forward and reverse primers into
Primer Parameters box !

17.

Check for homology with non-target genes, if found
select different primer set from PrimerQuest and !repeat !
In general:

a.

Want high homology with different variants of same
gene, to ensure that transcript variation does not
affect results !

b.

Want low homology with non-target genes, if primer
has less than four mismatches with a non-target
gene, pick new primers !

18.

Once an optimal primer set has been selected, return to
PrimerQuest (Integrated DNA Technologies)
(http://www.idtdna.com/site) !
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19.

Click the box for the forward and reverse primer set you
would like to purchase and click “Add Selected Assays
to Cart”

20.

A pop up will appear, click “Forward and Reverse
Primers”

21.

Then click “Oligos in Tubes”

22.

Confirm assay set and click “Continue”

23.

Change Scale to 25nmol DNA oligo !

24.

Change Purification to Standard Desalting !

25.

Name Sequence with gene and forward or reverse !

26.

Click “Add and Checkout”

27.

Once in cart, click edit on each primer sequence. Change
Normalization to “LabReady” !Click Add to Order

28.

Note the size of the expected amplicons, add the
sequence and accession number to the qPCR manual for
the lab

29.

Place order, each primer pair should be approximately
$20 ($10 each forward and reverse) !
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Appendix F: qPCR PROTOCOL (SOP7105)

SOP7105
REV A
Page 1 of 2
qPCR
Purpose: to prepare and perform qPCR
Approx. Time: Procedure:
❶ Pictures
2 hour prep, 1
1/2 hours to run A. PCR Preparation
Abbreviations: 1. Plan out plate map (you will need 3 technical
replicates for each sample per GOI and 1 non template
1. GOI = Gene
control for each GOI)
of Interest
2. Calculate MM for each GOI (dependent on the
2. MM =
amount of samples; one well = one reaction)
Master Mix
2.1. Include 10% for pipetting errors
3. NTC = Non
Template
Table 1: Primer Master Mix Volumes
Control
SOLUTION
AMOUNT PER
REACTION (uL)
Reminders:
1. Use aseptic
Fast SYBR Green
5
technique!
10 uM Primer
0.6
2. Our protocol
Water
11.2
has been
modified to
B. PCR
use 5 uL
3. Turn on hood
SYBR Green
3.1. Hood must run for at least 1 hour prior to usage
per reaction
4. While hood is running, turn on the qPCR 7500 Fast
rather than the
System and connected lap top and prepare the run
suggested
4.1. Name plate, input your name and any desired
volume of 10
additional notes
uL per
4.2. Select SYBR Green as detector (ROX will be the
reaction.
passive reference)
3. Keep qPCR
4.3. Input sample ID and GOI for each well (this is not
Master Mix
required, but will help with data analysis)
on ice (or on a
4.3.1. Also input whether the sample is
frozen tube
“standard” or “NTC”
rack)
4.3.1.1.
“Standard” will be wells containing
4. Fast SYBR
a sample
Green is light
4.3.1.2.
“NTC” will be wells contain a NTC
sensitive!
5. Spray down hood thoroughly with ethanol and wipe
with kim wipes
6. Bring all necessary supplies to hood (pipette, pipette
tips, Fast SYBR Green, 10 uM primers, RNase free
water, samples, 96-well plate, plate cover, frozen plate
holder and waste beaker)
7. Prepare MM for each GOI
8. Place 96-well plate in frozen plate holder
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Materials:
1. Fast SYBR
Green
2. Fast 96-well
PCR plates
3. Plate covers
4. 10 uM primers
5. RNase free
water
6. Frozen PCR
plate holder
7. Ethanol
8. Kim Wipes
9. Pipette tips

qPCR
8.1. The plate holder will change color as it defrosts; if
you notice any change in color immediately obtain a
new frozen plate holder from the freezer
9. Pipette 16.8 uL of appropriate primer MM into each
well
10. Pipette 3.2 uL of appropriate cDNA template into
each well
11. Pipette 3.2 uL of RNase free water into NTC wells
12. Secure plate cover onto 96-well plate
13. Briefly centrifuge
14. Place in qPCR machine (7500 Fast System) and run
cycle as listed in Table 2.
14.1. Add a dissociation cycle to the plate run
Table 2: Fast SYBR Green System Information for 7500
Fast System
Temperature
Duration
Cycle
95.0°C
20 sec
HOLD
95.0°C
3 sec
60.0°C
30 sec
40
15. A pop up will appear once run is complete, save the
document and see SOP for qPCR Data Analysis for
further instructions
C.
1.
2.
3.
4.

Clean-up & Storage Instructions
Discard pipette tips and empty tubes in biohazard
Return all supplies to appropriate location
Clean hood with ethanol and kim wipes
Fast SYBR Green should be stored at -20°C prior to
first thaw. After first thaw, Fast SYBR Green should
be stored at 4°C
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Appendix G: qPCR DATA ANALYSIS PROTOCOL (SOP7106)

SOP7106
REV B
Page 1 of 5
qPCR Data Analysis
Purpose: to perform qPCR Data Analysis
Approx. Time: Procedure:
Dependent on
number of
A. Analyzing qPCR Results on
samples
1. Upon completion of a qPCR run, begin by reviewing the “Spectra” tab. You are mainly
concerned with column “A” as it is the column that detects SYBR Green fluorescence.
Abbreviations:
Highlight all wells for a particular gene of interest, and slide the “cycle” box upwards. You
Ct = Threshold
should see the fluorescence increasing, as seen in the following Figures 1 and 2.
Cycle
SE = Standard
Error
STDEV =
Standard
Deviation
n= sample size
s = STDEV of
∆Ct
Reminders:
Don’t forget to
check cycle
threshold values
for reference
genes for all
samples of
interest!

Figure 1: Spectra for a single gene of interest at 0 cycles.

!

!

Figure 2: Spectra for a single gene of interest at 40 cycles.
!

125

!

SOP7106
REV B
Page 2 of 5
qPCR Data Analysis
2. Next, view the “Amplification Plot” tab. The instrument can “Auto” calculate the Ct for you,
however you will want to review the output to ensure that it has indeed been analyzed correctly.
2.1. Baseline should be set for cycles prior to exponential amplification. The raw amplification
plot in Figure 3 baseline should be 3 cycles – 17 cycles.
2.2. Place the threshold cycle (red line) in the middle of the subsequent linear region (as seen in
Figure 4).
2.3. Click File, export, results.

!

Figure 3: Raw amplification plot for a specific gene of interest.

Figure 4: Amplification plot after being analyzed.
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!

3. Next, click the “Dissociation Curve” tab. Ensure that all wells containing samples are melting
at the same temperature, as seen in Figure 5.

Figure 5: Ideal dissociation curve for a specific primer.

!

4. Prior to data analysis, you will want to review the analyzed amplification plots for each
triplicate set of samples for each gene of interest. You can do this by highlighting the
appropriate wells on the “Amplification Plot” tab after data analysis. All triplicate values
should have the same slopes. Wells with different slopes should be considered and outlier and
removed from the data set. See Figures 6 and 7 for examples of amplification plots with and
without outliers.

!

Figure 6: Example of triplicate samples for single gene that do not have any outliers.
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!

Figure 7: Sample in purple to the left is an outlier and should be excluded from the analysis.
5. Lastly, you will need to review the dissociation curve for outliers as well. Figure 8 provides an
example of a dissociation curve with outliers. The sample in red was removed from data
analysis as it formed shorter, sequences of DNA, different than those in all other wells.

!

Figure 8: Dissociation curve that contains an outier (in red).
B. Reference Gene Validation
6. Average triplicate Ct values for each sample for each reference gene of interest
7. Plot average Ct values for each sample group on a bar chart
7.1. Calculate SE using the following equation for the error bars
!" =

!"#$%
!

8. Perform a one-way ANOVA with a 95% confidence interval to ensure there is no significant
difference between samples
8.1. If p < 0.05 the reference gene cannot be used for the samples selected
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C. Relative Expression Analysis
9. Average triplicate Ct values for each sample/primer set
10. Normalize samples to the appropriate reference gene using the below equation
∆!" = ! !"!"#$!!"#$%& − ! !"!"#$!!"#"!"$%"!!"#"
11. In order to obtain fold change data, an experimental and control group must be analyzed.

Subtract the ∆Ct of control samples from the ∆Ct of experimental samples to obtain a ΔΔCt!
!
12. Calculate ΔΔCt by using the following equation!
!
!

∆∆!" = ∆!"!"#!$%&!'!"#!!"#$%&! − ∆!"!"#$%"&!!"#$%&!
13. Obtain fold change (relative expression of mRNA abundance) by plugging the ΔΔCt value
into the below equation!
!

!"#$!!ℎ!"#$ = 2!(∆∆!")

D. Calculating STDEV and SE
14. Calculate STDEV for each sample/primer set (including the reference gene, although this
should already be complete)
15. Calculate s (STDEV of ∆Ct) plugging in STDEV of reference gene and target sample
!
!
!!"#$%!!!"#$%& = ! !"#$%!"#"!"$%"!!"#!
+ !"#$%!"#$%!!!"#$%&

16. Calculate upper and lower limits on fold change values by adding or subtracting the value
obtained for s from the fold change value (see below equation)
!""#$!&!!"#$%!!"#"$% = !"#$!!ℎ!"#$! ± ! !!"#$%!!!"#$%&
17. Calculate SE for the fold change values (for error bars) with the below equation
!" =
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Appendix H: FORWARD AND REVERSE PRIMER SEQUENCES
Table 13: Selected Genes, Accession Numbers & Forward and Reverse Primer Sequences

Gene &

Forward Primer

Reverse Primer

Accession
Number

(5’ to 3’)

(5’ to 3’)

ACTB

CCACCATGTACCCTGGCATT

CGGACTCGTCATACTCCTGC

TCTGACGGCAACTTCAACTG

CGTCCCAAAGTAGGAGAGGA

CGACCACTTTGTCAAGCTCA

AGGGGAGATTCAGTGTGGTG

GTCCTATTGACATCGCCAGTAA

AAACAACAATCCGCCCAAAG

AGACATAGCCCCACCATGAG

CAAGGGTTGGGGTCAGTAGA

TGACTCGTGAGCACATCTTTAG

GGAGATTAGGAGCCAGTTTGAG

GCGGTGGGAAGATTACAAGA

TTTGGTGAGACCCACTTTCC

CTCTCCTTTCGTTGCCTGAT

CACCGATCTGTGAAGGAGTAAG

TACTGCTGAGCGTGAGATTG

GATGAAGGATGGCTGGAACA

AAGCACTAAGTCAGGAGATTGG

CGAGGTTTGTCTCCAGGTAAG

AAAGAGGCACTGGCAGAAA

CTCTGGCTTGTTCCTCACTAC

NM_001101
BAX
NM_138761
GAPDH
NM_001002
HPRT1
M31642
ICAM
J03132
Ki67
NM_002417
PECAM
NM_000442
RPS13
L01124
SMA
NM_001613
TF
J02931
IL-6
M54894
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Appendix I: CELL CULTURE & BVM CULTIVATION PROTOCOLS

SOP5103
REV A
Page 1 of 1
Thawing
Purpose: The purpose of this SOP is to guide the user in the thawing of cells frozen in liquid nitrogen.
Approx. Time:
Procedure:
❶
30 min
A. Preparation
Abbreviations:
1. Assure lab hygiene protocol has been followed
1. IPA – isopropyl alcohol 2. Place cell media into water bath to warm up
3. “Open” the hood by raising the door to the marked line and
turning on the light and pump
❷
4. Bring bottle of cell media into the hood
Reminders:
5. Fill flask with appropriate amount of media
1. Always spray items
5.1. Refer to ❶
with IPA before
6. Acquire Dewar Cell Notebook and find the desired cell type and
placing them in the
hood.
location
2. Be careful not to get
6.1. Location is based on canister -> cane -> position
water near the o-ring
7. Take sticker out of the notebook and place it in your lab
of the vial when
notebook
thawing the cells.
3. Minimize the time the
Dewar is open to
prevent vaporization
of nitrogen
4. Temperature
insulating gloves are
available next to the
Dewar for safety
5. Always wear shoes,
pants, & goggles
working with the
Dewar

B. Thawing
1. Open Dewar
2. Carefully take out the correct canister and cane ❷
3. Located the position of the desired cell vial on the rod
4. Take the vial off, put cane into the Dewar, and close the Dewar
5. While holding the top of the vial, swirl the frozen vial in the
water bath to thaw
5.1. The vial may hiss and pop-- this is normal
6. Once the vial is thawed, spray down with IPA
7. Bring the thawed vial into the hood and loosen its cap
8. Pipette the cell solution into flask of media ❸
8.1. Ensure the whole cell solution is taken
9. Place the flask in the incubator
10.
Congratulations, you have successfully thawed your cells!

Materials:
1. 70% IPA
2. Cell flask
3. Cell Media
4. Dewar Notebook
5. Pipette

Revision History:
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Jakub Truty

Summer 2013
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❸

Flask
T-25
T-75

Media
9 ml
20 ml

SOP5104
REV A
Page 1 of 2
Passing Cells
Purpose: The purpose of this SOP is to guide the user in the method of passing cells.
Approx. Time: 45 min. Procedure:
A. Preparation
Abbreviations:
1. IPA – isopropyl alcohol 1. Assure lab hygiene protocol has been followed
2. DCF-PBS – Di-cation
2. Place cell culture media and trypsin in water bath to warm up.
free phosphate
3. “Open” the hood by raising the door to the marked line and
buffered solution
turning on the light and pump
3. HUVEC – Human
4. Wipe down hood with 70% IPA
umbilical vein
5. Wipe microscope stage with 70% IPA
endothelial cell
6. Check confluency of the cells ❶
Reminders:
6.1. Do not pass HUVEC if under confluent
1. Always spray items
7. Place flask back into the incubator until ready to pass.
with IPA before
8. Acquire bag with new flasks and bring into hood.
placing them in the
8.1. Do not lay bag down on surface
hood
2. Spray hands with IPA
8.2. Remember that the inside of the bag is a sterile
often, particularly
environment—never put your hand inside
after taking them out
8.3. While holding the outside of the bag with one hand, gently
of the hood.
let a flask fall into your other hand
3. Avoid messiness in the
8.4. Securely tape bag closed, remove from hood, & stash away
hood
9. Label new flasks with cell type, initials, pass #, and date:
4. Remember that
yearmonthday ❷
pipettes can typically
10. Spray down bottle of media and bring into hood
hold more volume
10.1. Uncap using sterile technique
than they are labeled
5. Be mindful of the cell
10.2. Place appropriate amount of media into new flasks ❸
type you are working
10.3. Place new flasks into incubator to stay warm for at least 30
with—some are more
minutes if coating a flask
fragile than others
6. Always carry flask
tilted bottom end
down
7. Have passage ratio
calculated prior to
beginning this
protocol

Materials:
1. 70% IPA
2. Flask
3. Cell Media - warm
4. Trypsin - warm
5. DCF-PBS
6. Pipettes (various sizes)

B. Passing
1. Bring old flask out of incubator and aspirate old media out
2. Pour a small amount (5-10 mL) of DCF-PBS in flask to rinse off
the media
2.1. Rock the flask back and forth to allow DCF-PBS to cover floor
completely
2.2. Aspirate out
3. Use the vortex mixer to mix the 15 mL conical of trypsin
4. Pipette appropriate amount of trypsin into flasks ❸
4.1. Allow trypsin to cleave the cells off the bottom of the flask
by placing into the incubator for 2-3 minutes
4.1.1. While waiting, bring new flasks back into the hood
4.2. To guide the process, firmly tap the flask against the bottom
of your palm
4.3. Observe under microscope; if most cells are freely floating
as seen in ❹, the process is complete.
5. Deactivate with 1:1 ratio of media:trypsin
5.1. For HUVEC, deactivate with 2:1 ratio of media:trypsin
6. “Rinse the driveway” by pipetting solution inside the flask
against the flask bottom several times
7. Jam the pipette tip into the corner of the flask and pipette in and
out several times to break up clumps
7.1. Avoid creating bubbles during this step
8. Pipette out and put appropriate amount into each new flask
9. Place new flasks into the incubator
10. Dispose of old flask into the biohazard
11. “Close” the hood by wiping down all surfaces with 70% IPA,
turning off the pump and light, and pulling down the hood door
to 75% closed.
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❶ on page 2

❷

❸
Flask
T-25
T-75
T- 225
❹

Media
4 ml
12 ml
36 ml

Trypsin
1 ml
3 ml
9 ml

SOP5104
REV A
Page 2 of 2
Passing Cells
❶ Confluency Reference

<20%
Flask
T-25
T-75
T-225

< 200,00 thousand
< .5 million
< 1.5 million

Revision History:
A
Jakub Truty

~40-50%

~80%
Approx. # of Cells (HUVEC)
500 thousand
1 million
1.5 million
2.5 million
3.5 million
8 million

Winter 2013
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>100% (overconfluent)
1-1.5 million
3-4 million
9-10 million

SOP5105
REV A
Page 1 of 1
Feeding Cells
Purpose: The purpose of this SOP is to guide the user in feeding cells during culturing.
Approx. Time: 20 min. Procedure:
A. Preparation
Abbreviations:
1. IPA – isopropyl alcohol 1. Assure proper lab hygiene has been followed
2. DCF-PBS – Di-cation
2. Place cell culture media water bath to warm up
free phosphate
3. “Open” the hood by raising the door to the marked line and
buffered solution
turning on the light and pump
3. HUVEC – Human
4. Wipe down hood with 70% IPA
umbilical vein
5. Wipe microscope stage with 70% IPA
endothelial cell
6. Check status of the cells
Reminders:
6.1. If cells are confluent, consider passing the cells (SOP5104)
1. Always spray items
7. Place flask back into the incubator until media is warmed up
with IPA before
8. Write down volume of cell media needed in your lab notebook
placing them in the
8.1. Refer to ❶
hood
2. Spray hands with IPA
often, particularly
after taking them out
of the hood.
3. Avoid messiness in the
hood
4. Remember that
pipettes can typically
hold more volume
than they are labeled
5. Be mindful of the cell
type you are working
with—some are more
fragile than others
6. Always carry flask
tilted bottom end
down

B. Feeding
1. Bring the cell media into the laminar flow hood
2. Bring cell flask out of incubator into the flow hood
3. Open an aspirating pipette and connect to pump tubing
4. Uncap cell flask and tilt towards one of the back corners ❷
5. Insert pipette and aspirate the media out of the cell flask
5.1. Be careful not to touch the pipette against the flask neck
5.2. Aspirate out all the cell media
6. Remove pipette, cap cell flask, and dispose of the pipette.
7. Uncap bottle of cell media
8. Open an appropriately sized pipette and attach to the pipette
aid
9. Pipette volume of cell media from step 8
10. Uncap cell flask and pipette media into the flask
11. Cap cell flask and dispose of the pipette
12. Place cell flask into the incubator
13. Place cell media to the refrigerator
14. “Close” the hood by wiping down all surfaces with 70% IPA,
turning off the pump and light, and pulling down the hood
door to 75% closed.

Materials:
1. 70% IPA
2. Flask with cells
3. Cell Media - warm
4. Pipettes (various sizes)

Revision History:
A
Jakub Truty

Spring 2014
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❶
Flask
T-25
T-75
T- 225
❷

Media
4 ml
12 ml
36 ml

BVM Setup- Dual Sod (Gravity Sod ECs)

Materials Needed:
•
•

•

•
•

-1 confluent T225 per cell type per vessel
Media (made prior)
o BR Media (about 200-250 ml per vessel)
o Conditioning Media (about 30 per trough plus 50 per conical)
o EC Media (enough for deactivation, combination spinning if necessary,
reservoirs, resuspending, and chaser)
o SMC Media (deactivation, combination if necessary, reservoirs, chaser,
resuspending)
o CellTracker and necessary media
Bioreactor Pieces
o Bioreactor chamber, lid, reservoir lid, tubing, internal scaffold flexible piece, AT
LEAST one male and one female stop cap per system
Sterile forceps
Scaffold cut and sutured to big female end and small male end

Procedure:
Conditioning Setup
1. Place all necessary media in water bath
a. Reservoir media, trough media
2. Bring scaffolds into hood in conicals
3. Transfer scaffolds with forceps into conicals with sterile 70% EtOH (about 10ml
depending on length) to sterilize for 30 min
4. Wipe down shelf, pump and cartridges with 70% IPA
5. Fill two troughs, one with DCF-PBS and one with Conditioning media
6. Open first sterilized chamber and fill with BR Media
a. Fill quite a bit when gravity sodding
7. Repeat with each chamber (up to 3)
8. Open conicals, stop caps, syringe, sterile forceps in hood then sterile gloves
9. Remove scaffold 1 from conical using sterile forceps and place in DCF-PBS trough
a. Or put all scaffolds at the same time with forceps
10. Use syringe to flush luminally 3X then add stop cap and flush transmurally 3X (use
female stop cap for transmural flush)
a. May see aneurism of the scaffold, do not apply pressure until aneurism ceases
11. Remove stop cap then repeat with Conditioning Media (be thorough!)
12. Remove stop cap and insert scaffold into Bioreactor (*careful not to kink scaffold)
13. Repeat steps 9-12 for each scaffold/system
14. Add stop caps to sodding inlets
15. Open lids in hood and place on chamber

135

16. Bring reservoirs full of conditioning media into hood
17. Open first conical then open reservoir cap and tubing (careful not to contaminate luer
lock ends)
*reservoir should be full to about 50 ml
18. Place lid on conical, open all stopcocks, and invert reservoir to prime system
19. Clamp tubing near reservoir and bring to big incubator
20. Repeat steps 17-19 for each system
21. Flow through lumen to remove all air then clamp lumen and condition transmurally at
150 RPM for 6 hours to overnight

Cell Tracker (cytoplasm is died)
Use ~ 1ml of pre-spun cell solution

Cell Sodding
1. Warm Media and Trypsin (for SMC)
2. Prepare reservoirs with 3:1 HUVEC/HUASMC media
*only 30-35 ml (I use 40 ml)
3. Harvest SMCs with Trypsin, deactivate at least 2:1, add small amounts to CT Control,
Stephan culture control, take sample for counting, then centrifuge on 4 for 4 min
a. Centrifuge twice if necessary (number of flasks) by aspirating ½ and recombining
to one conical, then spinning again
b. CT control goes in the circular well-plate. 1 well per cell type unmixed and 1 well
per cell type once mixed
c. Culture control is 1 T-75 per cell type per set up
4. While spinning (remember to balance centrifuge)
a) open 2 troughs, fill one with cell specific media, leave other empty for cell solution
b) grab syringe
c) bring systems into hood, angle sodding inlet stopper 45 degrees toward reservoir, and
unscrew reservoir caps
5. Aspirate media, then resuspend in 3 ml Cell Specific Media per vessel (so 9 ml if doing 3
vessels) and add to empty trough
6. Unclamp all systems and remove all sodding stopcaps
*Make sure lumen is closed so that flow is going transmurally!*
7. Wash driveway, break up clumps again with syringe then sod all in a row (very
SLOWLY! i.e. low pressure)
8. Chase all in a row using 3 ml cell media per vessel
9. Replace stop caps, close reservoir caps, clamp tubing
10. Bring systems to incubator very carefully to avoid media sloshing
11. Swap conditioning media reservoirs for combo cell media (quickly so that caps are not
off for much time)
12. Leave lumen clamped and run transmural flow at 10 RPM for 10 minutes
13. Turn pump off and let cells rest for 1-3 hours
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14. Count cells in sample
15. Repeat steps 4-5 for ECs
16. Aspirate media, then suspend in 0.25 ml Cell Specific Media per vessel and add to empty
trough
17. Unclamp all systems and remove all sodding stopcaps
*Make sure lumen is closed so that flow is going transmurally!*
18. Wash driveway, break up clumps again with syringe then sod all in a row (very
SLOWLY! i.e. low pressure)
19. Chase all in a row using .5 ml cell media per vessel
20. Replace stop caps, close reservoir caps, and clamp tubing
21. Complete 3 initial rotations with each system
a) 0, 180, 90, -90 degrees for 30 seconds each
22. Bring systems to incubator very carefully to avoid media sloshing
23. Continue same rotation pattern
a) Rotate every 4 minutes for 1 hour
b) Start at 180 (upside down)
24. Count cells in sample
25. Allow cells to rest for 1-3 hours
26. Unclamp lumen (TRANSLUMENAL FLOW) and maintain 15 RPM for 3-6 hours
a. LATEST PROCEDURE AS OF 6/17/14: 30 RPM for 1 hour, 45 RPM for 1
hour, 60 RPM for 1 hour, 75 RPM for one hour, 90 RPM for overnight
b. LASTEST PROCEDURE AS OF 7/17/14 for HUVEC and HUASMC dual
sodding: 30 RPM for 1 hour, 45 RPM for 30 min, 60 RPM for 1 hour, 75 RPM
for 1 hour, 90 RPM overnight
27. Increase flow to 30 RPM for 3 hours
28. Continue increasing flow by 15 RPM at a time until 90 RPM is reached
29. Replace media reservoirs every 3rd day

Take Down
1.
2.
3.
4.
5.
6.

Fill Dewie with Liquid Nitrogen from MATE room
Prep conicals and cryotubes with labels and fixative (gluteraldehyde)
Prep cutting board, forceps, hemostats, 11 blade, and big forceps
Fill one trough with DCF-PBS and grab a syringe
Bring 1st system to bench
Unscrew fittings and remove vessel. Place in PBS trough
*careful not to bend vessel at all!*
7. SLOWLY flush vessel with PBS
8. Cut vessel from fittings
9. Cut Proximal third and place in fixative with foil covering
10. Cut Medial third and place in (formalin) fixative with foil covering (labeled for Tanner)
11. Cut Distal third and place in CryoTube Vial then snap freeze for about 15-20 seconds
12. Place snap frozen piece in -20 freezer while taking down other vessels
13. Repeat steps 5-12 for each system
14. Bring snap frozen samples to -80 as fast as possible
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Appendix J: RNA QUALITY DATA – SPECTROPHOTOMETRY & GEL
ELECTROPHORESIS
Table 14: RNA Concentration and Quality Data for Umbilical Samples

Sample

Concentration (ng/μL)

A /A

1 Day Umbilical #1

226.2

2.06

2.10

1 Day Umbilical #2

150.8

2.05

0.66

1 Day Umbilical #3

258

2.08

1.55

1 Day Control HUVECs (p7)

7.4

1.59

0.10

1 Day Control HUASMCs (p6)

1.6

37.38

0.03

3 Day Umbilical Unstented #1

453.4

2.06

1.60

3 Day Umbilical Unstented #2

465

2.07

1.79

3 Day Umbilical Unstented #3

309.8

2.06

1.51

3 Day Umbilical Stented #1

255.7

2.08

2.18

3 Day Umbilical Stented #2

155.9

2.07

1.06

3 Day Umbilical Stented #3

182.5

2.07

0.86

3 Day Control HUVECs (p9)

214.3

2.04

1.44

3 Day Control HUVECs (p9)

299.1

2.06

1.49

3 Day Control HUASMCs (p7)

463.9

2.02

2.05

3 Day Control HUASMCs

222.9

2.04

1.98
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Table 15: RNA Concentration and Quality Data for Coronary Samples

Sample

Concentration (ng/μL)

A /A

1 Day Coronary #1

339.4

2.06

0.87

1 Day Coronary #2

369.4

2.05

0.90

1 Day Coronary #3

366.2

2.08

1.12

1 Day Control HCAECs

364.5

2.06

2.15

1 Day Control HCASMCs

302.6

2.05

2.03

3 Day Coronary Unstented #1

500.4

2.08

1.24

3 Day Coronary Unstented #2

502.4

2.07

1.85

3 Day Coronary Stented #1

270.1

2.04

0.56

3 Day Coronary Stented #2

160.1

2.01

2.31

3 Day Coronary Stented #3

428.4

2.07

1.70

3 Day Control HCAECs

245.8

2.04

1.75

3 Day Control HCAECs

649.1

2.04

2.22

3 Day Control HCASMCs

363.2

2.06

1.71

3 Day Control HCASMCs

320.9

2.07

2.07
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Table 16: RNA Concentration and Quality Data of Diabetic Samples

Sample

Concentration (ng/μL)

A /A

DHCAEC p4

258.3

1.96

2.10

DHCAEC p5

124.8

2.04

0.73

DHCAEC p6

110.8

2.03

0.66

DHCAEC p7

187.2

2.03

2.06

DHCAEC p8

177.5

2.03

2.04

DHCAEC p9

228.6

2.04

2.11

DHCASMC p6

333.4

2.04

2.04

DHCASMC p8

125.1

2.04

0.90

DHCASMC p9

101.7

2.01

0.79
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Figure 31: Pictured above is an ethidium bromide stained Agarose gel containing the
following RNA samples from the coronary sample group (from top to bottom): 3 Day
Coronary Unstented #1, 3 Day Coronary Unstented #2, 3 Day Coronary Stented #1, 3
Day Coronary Stented #2, 3 Day Coronary Stented #3, 3 Day Control HCAECs , 3 Day
Control HCAECs , 3 Day Control HCASMCs #1, and 3 Day Control HCASMCs #2.

Figure 32: Pictured above is an ethidium bromide stained Agarose gel containing the
following RNA samples from the coronary sample group (from top to bottom): 1 Day
Coronary #1, 1 Day Coronary #2, 1 Day Coronary #3, 1 Day Control HCAECs, and 1
Day Control HCASMCs.
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Figure 33: Pictured above is an ethidium bromide stained Agarose gel containing the
following RNA samples from the umbilical sample group (from top to bottom): 3 Day
Umbilical Unstented #1, 3 Day Umbilical Unstented #2, 3 Day Umbilical Unstented #3, 3
Day Umbilical Stented #1, 3 Day Umbilical Stented #2, 3 Day Umbilical Stented #3, 3
Day Control HUVECs (p9), 3 Day Control HUVECs (p9), 3 Day Control HUASMCs
(p7), and 3 Day Control HUASMCs.

Figure 34: Pictured above is an ethidium bromide stained Agarose gel containing the
following RNA samples from the umbilical samples (from top to bottom): 1 Day
Umbilical BVM #1, 1 Day Umbilical BVM #2, and 1 Day Umbilical BVM #3.
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Figure 35: Pictured above is an ethidium bromide stained Agarose gel containing the
following RNA samples from the diabetic sample group (from top to bottom):
DHCASMC (p9), DHCASMC (p8), DHCAEC (p9), DHCAEC (p8), DHCAEC (p7),
DHCAEC (p6), DHCAEC (p5), DHCASMC (p6), and DHCAEC (p4).
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Appendix K: CYCLE THRESHOLD VALUES USED FOR DATA ANALYSIS

The below tables contain the cycle threshold values used for data analysis in “Chapter 1:
GENE EXPRESSION IN UMBILICAL AND CORONARY BLOOD VESSEL MIMICS
AND DIABETIC CORONARY ARTERY ENDOTHELIAL AND SMOOTH MUSCLE
CELLS.” Outliers were identified from dissociation curves and amplification plots, which
are provided in “Appendix L: DISSOCIATION CURVES AND AMPLIFICATION
PLOTS,” and excluded from data analysis. Excluded outliers are in red font.

Table 17: Cycle Threshold Values for the 1 Day Umbilical Set-Up

CYCLE THRESHOLD VALUES FOR 1 DAY UMBILICAL SET-UP

BVM #1

BVM #2

BVM #3

GAPDH

ACTB

PECAM

SMA

ICAM

BAX

Ki67

16.7

18.8

22.9

19.4

21.0

21.4

26.0

16.9

19.2

22.9

19.5

20.8

22.5

25.3

16.9

19.6

23.3

19.8

21.2

23.1

26.3

17.3

17.5

25.7

20.6

20.3

23.8

27.3

17.5

20.3

25.5

21.6

21.2

24.4

27.3

17.5

19.5

25.3

21.7

21.9

39.1

27.5

16.6

16.5

22.9

18.7

21.4

22.2

26.1

16.7

18.3

22.4

18.3

20.7

22.6

26.6

16.9

18.0

22.7

19.3

19.7

23.6

26.5

*HUVEC and HUASMC cell flask from this set up did not yield RNA concentrations
high enough to perform qPCR.
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Table 18: Cycle Threshold Values for the 1 Day Coronary Set-Up

CYCLE THRESHOLD VALUES FOR 1 DAY CORONARY SET-UP

BVM #1

BVM #2

BVM #3

HCAECs

HCASMCs

GAPDH

ACTB

PECAM

SMA

ICAM

BAX

Ki67

18.1

21.8

28.1

24.6

22.2

23.9

27.6

19.8

18.2

27.8

24.9

22.3

24.1

27.4

18.2

21.8

28.1

25.0

23.4

24.4

27.2

18.6

21.1

25.8

23.6

22.5

22.7

25.8

18.2

21.3

25.5

24.2

22.0

23.3

26.4

18.5

21.7

26.1

25.0

22.7

23.0

26.8

18.6

21.3

26.7

23.3

22.1

23.7

26.8

18.7

21.2

26.5

24.7

22.1

23.9

26.6

18.6

24.9

27.0

24.5

22.7

24.6

27.3

17.1

19.4

23.9

22.5

23.8

21.2

25.5

17.3

19.7

23.8

22.0

23.6

22.0

26.3

17.5

19.7

24.4

23.3

24.4

23.0

26.6

17.3

19.6

30.1

18.1

21.7

24.2

30.4

17.2

20.8

29.4

19.9

22.6

24.9

29.7

17.2

20.0

29.7

19.0

22.6

25.3

30.0
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Table 19: Cycle Threshold Values for the 3 Day Umbilical Set-Up

CYCLE THRESHOLD VALUES FOR 3-DAY UMBILICAL SET-UPS

BVM #1

BVM #2

BVM #3

S-BVM #1

S-BVM #2

S-BVM #3

HUVECs

HUASMCs

GAPDH

ACTB

PECAM

SMA

ICAM

BAX

Ki67

17.2

16.7

27.7

20.8

28.1

23.9

n/a

16.9

16.9

27.4

21.2

28.0

20.1

17.1

16.9

28.4

22.4

28.0

20.7

17.0

15.6

27.6

18.8

25.2

n/a

n/a

17.1

15.6

27.4

19.2

25.3

17.1

15.8

27.6

19.1

25.5

17.1

16.5

29.6

20.9

29.7

n/a

n/a

17.2

16.6

30.1

21.4

30.0

17.1

16.5

30.1

21.5

30.0

16.7

16.4

25.0

20.0

24.8

25.4

25.1

16.7

16.5

25.1

20.1

24.9

25.5

25.2

16.9

16.6

24.8

20.8

25.0

23.1

25.1

17.3

18.0

25.4

19.8

25.8

22.2

n/a

17.3

18.2

25.9

20.3

25.5

20.2

17.2

18.5

26.2

21.2

25.9

21.2

17.2

16.0

27.1

24.4

27.6

n/a

n/a

17.3

16.1

27.1

23.1

28.0

17.4

16.4

26.2

23.4

28.5

17.0

16.3

22.3

25.6

27.2

n/a

21.8

17.1

16.3

22.4

27.2

27.4

21.0

17.2

16.6

22.5

27.5

27.8

22.5

18.3

22.3

30.9

21.5

25.8

24.6

30.0

18.4

22.5

31.1

22.3

25.6

24.7

30.3

18.4

22.1

31.7

22.4

26.0

24.7

28.8
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Table 20: Cycle Threshold Values for the 3 Day Coronary Set-Up

CYCLE THRESHOLD VALUES FOR 3-DAY CORONARY SET-UPS

BVM #1

BVM #2

S-BVM #1

S-BVM #2

S-BVM #3

HCAECs

HCASMCs

GAPDH

ACTB

PECAM

SMA

ICAM

BAX

Ki67

17.2

17.6

27.9

23.2

22.1

21.6

24.0

17.3

19.0

28.5

22.8

22.3

22.6

24.5

17.6

18.1

28.4

22.8

23.2

23.5

24.6

17.7

18.5

28.1

23.2

23.4

22.7

24.3

18.1

18.4

27.0

23.2

22.2

23.0

25.2

18.3

18.8

28.2

23.6

23.6

24.0

25.7

18.9

25.8

28.4

25.3

23.6

24.7

26.3

19.1

26.2

29.5

25.9

24.1

25.1

26.4

19.4

27.0

28.7

26.6

24.7

26.1

26.3

19.2

24.9

28.7

25.5

23.6

24.8

26.2

19.2

25.5

29.3

26.9

23.7

25.2

26.3

19.2

24.7

29.4

27.3

24.1

26.0

26.4

18.4

18.6

27.6

23.2

22.0

23.2

26.2

18.5

20.8

28.3

24.2

22.3

23.7

26.7

18.4

19.3

28.0

23.4

23.1

23.4

26.2

17.2

20.0

23.0

22.7

24.6

22.8

27.0

17.5

19.7

24.1

23.0

24.9

22.9

26.8

17.3

20.2

23.6

23.2

25.0

22.4

27.0

16.5

19.8

29.1

17.1

21.4

23.1

28.3

16.7

20.1

29.9

17.6

22.1

23.4

28.5

16.8

20.6

29.3

18.1

22.3

24.1

29.3

*Only 2 un-stented BVMs were cultivated for this set up, as one of the bioreactors
malfunctioned.
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Table 21: Cycle Threshold Values for the Diabetic Cell Flasks (Part 1)

CYCLE THRESHOLD VALUES FOR DIABETIC CELL FLASKS
Sample

HPRT1

RPS13

ACTB

PECAM

SMA

DHCAE
C p4

21.390
21.373
22.492
20.049
21.232
21.187
20.398
21.573
20.708
21.671
20.320
21.038
19.316
20.221
20.097
21.146
21.045
19.859
22.037
21.748
20.900
20.856
20.128
20.820
20.370
20.315
21.292

16.470
18.316
17.560
16.530
18.123
18.256
18.043
17.091
17.273
20.826
17.475
16.769
17.636
17.624
18.030
16.538
17.189
17.396
17.697
18.033
18.506
17.804
18.340
18.346
18.098
18.286
18.240

19.543
19.466
19.393
18.087
17.802
17.793
19.765
19.556
19.611
19.505
19.186
19.346
20.203
20.113
20.000
20.220
20.170
20.213
18.422
18.517
18.354
18.683
19.060
18.967
20.469
20.550
20.581

22.323
22.265
22.287
23.164
23.175
23.264
25.004
25.152
25.019
ERROR
25.145
24.543
24.624
24.885
24.607
25.482
25.573
25.500
27.890
28.072
28.276
29.451
29.477
29.567
28.064
28.336
28.280

23.493
23.610
23.719
21.277
21.350
22.006
22.659
22.743
23.186
22.551
22.794
23.294
21.312
21.905
22.754
23.085
23.248
23.714
17.742
18.247
19.030
17.115
17.515
18.180
18.424
19.300
19.956

DHCAE
C p5
DHCAE
C p6
DHCAE
C p7
DHCAE
C p8
DHCAE
C p9
DHCAS
MC p6
DHCAS
MC p8
DHCAS
MC p9
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Table 22: Cycle Threshold Values for Diabetic Cell Flasks (Part 2)
CYCLE THRESHOLD VALUES FOR DIABETIC CELL FLASKS
Sample
ICAM
TF
IL-6
BAX
Ki67
DHCAEC
21.527
31.201
23.328
21.744
23.608
p4
22.462
31.346
23.866
21.868
23.484
22.558
31.072
24.458
21.931
23.695
DHCAEC
20.121
27.265
21.472
20.900
26.069
p5
20.883
28.140
22.230
20.943
25.203
21.106
27.640
22.492
21.087
26.012
DHCAEC
21.688
29.517
21.917
21.968
27.084
p6
22.075
30.398
22.489
22.201
27.071
22.136
30.052
22.560
22.186
26.748
DHCAEC
22.269
29.548
22.017
22.081
27.215
p7
22.812
29.634
22.833
22.176
26.381
23.138
28.354
23.202
22.356
27.397
DHCAEC
23.384
29.198
22.648
22.386
27.514
p8
23.473
28.829
23.213
22.762
27.029
23.737
29.406
23.558
22.496
28.126
DHCAEC
22.055
30.358
16.632
23.097
34.471
p9
22.358
30.108
17.389
23.047
28.278
22.605
29.462
17.681
23.207
27.689
DHCASMC
22.652
21.543
16.632
21.929
25.650
p6
23.261
22.133
17.390
22.112
25.981
23.406
22.015
17.681
22.176
26.3588
DHCASMC
19.458
24.103
17.395
22.418
17.230
27.289
p8
19.717
23.994
17.936
22.605
17.966
27.082
19.985
23.748
17.792
22.449
ERROR
DHCASMC
21.482
24.345
17.230
23.850
25.642
p9
22.020
24.756
17.966
24.173
26.493
22.210
24.442
17.709
24.059
25.969
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Appendix L: DISSOCIATION CURVES AND AMPLIFICATION PLOTS

Figure 36: GAPDH amplification plot for coronary and umbilical samples.

Figure 37: GAPDH dissociation curve for umbilical and coronary samples.
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Figure 38: ACTB amplification plot for umbilical and coronary samples.

Figure 39: ACTB dissociation curve for umbilical and coronary samples.

151

Figure 40: ICAM amplification plot for coronary and umbilical samples.

Figure 41: ICAM dissociation curve for diabetic and umbilical samples.
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Figure 42: PECAM amplification plot for coronary and umbilical samples.

Figure 43: PECAM dissociation curve for umbilical and coronary samples.
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Figure 44: SMA amplification plot for umbilical and coronary samples.

Figure 45: SMA dissociation curve for umbilical and coronary samples.
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Figure 46: BAX amplification plot for umbilical and coronary samples.

Figure 47: BAX dissociation curve for umbilical and coronary samples.
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Figure 48: Ki67 amplification curve for umbilical and coronary samples.

Figure 49: Ki67 dissociation curve for umbilical and coronary samples.
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Figure 50: ACTB amplification plot for diabetic cell samples.

Figure 51: ACTB dissociation curve for diabetic cell samples.
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Figure 52: RPS13 amplification plot for diabetic cell samples.

Figure 53: RPS13 dissociation curve for diabetic cell samples.
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Figure 54: HPRT1 amplification plot for diabetic cell samples.

Figure 55: HPRT1 dissociation curve for diabetic cell samples.
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Figure 56: TF amplification plot for diabetic cell samples.

Figure 57: TF dissociation curve for diabetic cell samples.
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Figure 58: IL-6 amplifiation plot for diabetic cell samples.

Figure 59: IL-6 dissociation curve for diabetic cell samples.
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Figure 60: PECAM amplification plot for diabetic cell samples.

Figure 61: PECAM dissociation curve for diabetic cell samples.
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Figure 62: SMA amplification plot for diabetic cell samples.

Figure 63: SMA dissociation curve for diabetic cell samples.
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Figure 64: ICAM amplification plot for diabetic cell samples.

Figure 65: ICAM dissociation curve for diabetic cell samples.
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Figure 66: BAX amplification plot for diabetic cell samples.

Figure 67: BAX dissociation curve for diabetic cell samples.
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Figure 68: Ki67 amplification plot for diabetic cell samples.

Figure 69: Ki67 dissociation curve for diabetic cell samples.
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